Integrated Environmental Technologies 10-K 28 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 27, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'INTEGRATED ENVIRONMENTAL TECHNOLOGIES, LTD.	'	'
Entity Central Index Key	'0001084031	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Document Period End Date	31-Dec-13	'	'
Document Type	'10-K	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$5,768,000
Entity Common Stock, Shares Outstanding	'	230,778,176	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash	$1,049,399	$180,489
Accounts receivable	28,250	29,212
Prepaid expenses	26,166	15,933
Inventory	126,952	82,566
Note receivable	'	7,762
Total current assets	1,230,767	315,962
Property and equipment, net	344,884	282,982
Total assets	1,575,651	598,944
Current liabilities:	'	'
Accounts payable	41,320	249,474
Accrued expenses	47,954	159,963
Customer deposits	38,109	36,109
Convertible debentures	25,000	25,000
Note payable	75,513	'
Total current liabilities	227,896	470,546
Convertible debentures	476,125	476,125
Note payable	46,546	'
Total liabilities	750,567	946,671
Commitments and contingencies	'	'
Stockholders' equity (deficiency):	'	'
Common stock, $.001 par value; 400,000,000 shares authorized; 229,971,926 and 150,368,500 shares issued and outstanding, respectively	229,972	150,369
Additional paid-in capital	20,075,764	17,151,303
Accumulated deficit	-19,480,652	-17,649,399
Total stockholders' equity (deficiency)	825,084	-347,727
Total liabilities and stockholders' equity (deficiency)	$1,575,651	$598,944

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Balance Sheets [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	229,971,926	150,368,500
Common stock, shares outstanding	229,971,926	150,368,500

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues:	'	'
Sales	$93,866	$92,658
Leasing and Licensing Fees	52,500	62,395
Total revenues	146,366	155,053
Cost of sales	28,930	25,794
Gross profit	117,436	129,259
Operating expenses:	'	'
General and administrative expense	1,243,196	1,195,720
Sales and marketing expense	447,832	495,038
Research and development expense	211,822	295,788
Total operating expenses	1,902,850	1,986,546
Loss from operations	-1,785,414	-1,857,287
Other income (expense):	'	'
Interest income	74	1,432
Interest expense	-45,913	-69,643
Total other income (expense)	-45,839	-68,211
Net loss	($1,831,253)	($1,925,498)
Net loss per share, basic and diluted	($0.01)	($0.01)
Weighted average shares outstanding, basic and diluted	187,333,118	140,233,176

Statements_of_Stockholders_Equ

Statements of Stockholders Equity Deficiency (USD $)	Total	Common Stock	Additional Paid-in Capital	Stockholders' Deficit
Beginning Balance at Dec. 31, 2011	($790,981)	$122,735	$14,810,185	($15,723,901)
Beginning Balance, shares at Dec. 31, 2011	'	122,735,165	'	'
Common stock issued for cash, net of offering costs	1,529,900	20,375	1,509,525	'
Common stock issued for cash, net of offering costs, shares	'	20,375,000	'	'
Common stock issued as payment on principal and interest on convertible debentures	197,148	2,186	194,962	'
Common stock issued as payment on principal and interest on convertible debentures, shares	'	2,185,585	'	'
Common stock issued as payment on principal and interest on convertible promissory notes	436,165	4,603	431,562	'
Common stock issued as payment on principal and interest on convertible promissory notes, shares	'	4,602,750	'	'
Common stock issued as payment of accounts payable	41,000	460	40,540	'
Common stock issued as payment of accounts payable, shares	'	460,000	'	'
Stock-based compensation	164,539	10	164,529	'
Stock-based compensation, shares	'	10,000	'	'
Net loss	-1,925,498	'	'	-1,925,498
Balance at Dec. 31, 2012	-347,727	150,369	17,151,303	-17,649,399
Balance, shares at Dec. 31, 2012	'	150,368,500	'	'
Common stock issued for cash, net of offering costs	2,763,605	74,388	2,689,217	'
Common stock issued for cash, net of offering costs, shares	'	74,388,766	'	'
Common stock issued as payment on principal and interest on convertible debentures	38,090	401	37,689	'
Common stock issued as payment on principal and interest on convertible debentures, shares	'	400,947	'	'
Common Stock Issued As Settlement Of Litigation	26,550	450	26,100	'
Common Stock Issued As Settlement Of Litigation, Shares	'	450,000	'	'
Common stock issued as payment of accounts payable	70,250	1,714	68,536	'
Common stock issued as payment of accounts payable, shares	'	1,713,839	'	'
Stock-based compensation	105,569	2,650	102,919	'
Stock-based compensation, shares	'	2,649,874	'	'
Net loss	-1,831,253	'	'	-1,831,253
Balance at Dec. 31, 2013	$825,084	$229,972	$20,075,764	($19,480,652)
Balance, shares at Dec. 31, 2013	'	229,971,926	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($1,831,253)	($1,925,498)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	172,234	118,751
Stock-based compensation expense	105,569	164,539
Stock issued as settlement of litigation	26,550	'
Write-off of accounts receivable	2,341	828
Write-off of lease receivable	'	20,113
Changes in operating assets and liabilities:	'	'
Accounts receivable	-11,879	-22,168
Prepaid expenses	-10,233	-5,006
Lease receivable	'	13,883
Note receivable	3,590	13,036
Inventory	-60,015	-25,485
Other receivable	'	12,081
Accounts payable	-123,232	67,802
Accrued expenses	-73,919	77,140
Customer deposits	2,000	-5,420
Net cash used in operating activities	-1,798,247	-1,495,404
Cash flows from investing activity:	'	'
Purchase of equipment	-66,507	'
Cash flows from financing activities:	'	'
Proceeds from sale of common stock, net of offering costs	2,763,605	1,529,900
Repayment of note payable	-29,941	'
Net cash provided by financing activities	2,733,664	1,529,900
Increase in cash	868,910	34,496
Cash - beginning of period	180,489	145,993
Cash - end of period	1,049,399	180,489
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	5,032	1,053
Cash paid for income taxes	'	5,462
Noncash operating activities:	'	'
Issuance of 1,713,839 and 360,000 shares of common stock, respectively, as payment of director fees	70,250	36,000
Issuance of 400,947 shares of common stock as payment of interest on convertible debenture	38,090	'
Issuance of 450,000 shares of common stock as settlement of litigation	26,550	'
Issuance of 100,000 shares of common stock as payment of accounts payable	'	5,000
Noncash investing activity:	'	'
Issuance of note payable as payment for equipment	152,000	'
Noncash financing activities:	'	'
Issuance of 1,649,874 shares of common stock as payment of offering costs related to private placements	109,100	'
Issuance of warrant to purchase 401,567 shares of common stock as payment of offering costs related to private placements	23,188	'
Issuance of 2,185,585 shares of common stock as payment of principal and interest due on convertible debentures	'	197,148
Issuance of 4,602,750 shares of common stock as payment of principal and interest due on convertible promissory notes	'	$436,165

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Statement Of Cash Flows [Abstract]	'	'
Common stock issued as payment of director fees	1,713,839	360,000
Issuance of common stock convertible debentures shares	'	2,185,585
Common stock shares issued as settlement of litigation	450,000	'
Common stock issued as payment of accounts payable, shares	'	100,000
Common stock issued as payment offering costs related to private placements	1,649,874	'
Common stock warrants issued as payment offering costs related to private placements	401,567	'
Common stock issued as payment of interest on convertible debenture	400,947	'
Issuance of common stock convertible promissory notes shares	'	4,602,750

Organization_and_Description_o

Organization and Description of Business	12 Months Ended
	Dec. 31, 2013
Organization and Description Of Business and Basis Of Presentation [Abstract]	'
Organization and Description of Business	'
	1	Organization and Description of Business
	Integrated Environmental Technologies, Ltd. (the “Company”) was originally incorporated in Delaware on February 2, 1999 and is currently a Nevada corporation.  The Company is headquartered in Little River, South Carolina and operates through its wholly-owned subsidiary, I.E.T., Inc., a Nevada corporation incorporated on January 11, 2002.
	The Company markets its products and equipment under the umbrella brand name, EcoTreatments™.  The Company produces and sells a hypochlorous acid solution (“Anolyte”) as well as an anti-oxidizing, mildly alkaline solution (“Catholyte”) that provide an environmentally friendly alternative for cleaning, sanitizing and disinfecting as compared to the hazardous chemicals traditionally prevalent in commercial use.  The Company markets and sells Anolyte under the brand name Excelyte™ and sells Catholyte under the brand name Catholyte Zero™.  The Company manufactures proprietary equipment, which its markets under the brand name EcaFlo™, to produce Anolyte and Catholyte solutions for distribution by the Company and, under certain circumstances, such equipment is leased by the Company to customers for use at a customer’s facility.

Basis_of_Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Organization and Description Of Business and Basis Of Presentation [Abstract]	'
Basis of Presentation	'
	2	Basis of Presentation
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant recurring operating losses and negative cash flows from operations.  The Company has a working capital of $1,002,871 and an accumulated deficit of $19,480,652 as of December 31, 2013.  The Company has no lending relationships with commercial banks and is dependent on the completion of financings involving the private placement of its securities in order to continue operations.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company does not anticipate establishing any lending relationships with commercial banks in the foreseeable future due to its limited operations and assets.  The Company continues to execute its strategy of selling Anolyte and Catholyte solutions and leasing its EcaFlo™ equipment to fund its operations and is focused on obtaining additional capital through the private placement of its securities.  The Company is pursuing potential equity and/or debt investors and, from time to time, has engaged placement agents to assist it in this initiative.  While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts.  If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company.  Any additional equity financing may result in substantial dilution to the Company’s stockholders.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3.	Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary.  All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
	Although the Company regularly assesses these estimates, actual results could differ materially from these estimates.  Changes in estimates are recorded in the period in which they become known.  The Company based its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.  Actual results may differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate.  All of these estimates reflect management's best judgment about current economic and market conditions and their effects based on information available as of the date of these consolidated financial statements.  If such conditions persist longer or deteriorate further than expected, it is reasonably possible that the judgments and estimates could change.
	Concentration of Credit Risk
	The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.  The Company’s financial instruments that are exposed to concentration of credit risks consist primarily of cash.  The Company maintains its cash in bank accounts which, at times, exceed federally-insured limits.
	The Company sells its products to customers in diversified industries and geographical regions.  During the year ended December 31, 2013, four customers accounted for 22%, 14%, 14% and 11%, respectively, of revenues.  For the year ended December 31, 2012, two customers accounted for 35% and 29%, respectively, of revenues.  No other customer accounted for more than 10% of the Company’s revenues during the year ended December 31, 2013 or 2012.  We regularly evaluate the creditworthiness of the Company’s customers.
	Accounts Receivable
	Accounts receivable consist of trade receivables recorded at original invoice amount, less any allowance for uncollectible accounts.  Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest.  Trade receivables are periodically evaluated for collectability by considering a number of factors, including the length of time an invoice is past due, the customer’s creditworthiness and historical bad debt experience.  Changes in the estimated collectability of trade receivables are recorded in the results of operations for the period in which the estimate is revised.  Trade receivables that are deemed uncollectible are offset against the allowance for uncollectible accounts.  The Company generally does not require collateral for trade receivables.
	Inventory
	Inventory is recorded at the lower of cost or market using the first-in, first-out method.  The Company determines its reserve for obsolete inventory by considering a number of factors, including product shelf life, marketability, and obsolescence.  The Company determines the need to write down inventories by analyzing product expiration, market conditions, and salability of its products.
	Property and Equipment
	Property and equipment are recorded at cost less allowances for depreciation.  The straight-line method of depreciation is used for all property and equipment.  Repair and maintenance costs are expensed as incurred.  Equipment is depreciated over an estimated useful life ranging from three to seven years.   Leasehold improvements are depreciated over the shorter of the original term of lease or the estimated useful life of the improvement.
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments, which include cash, accounts receivable, lease receivables, accounts payable and accrued expenses, approximate their fair values due to their short maturities.
	The fair value of the note receivable, notes payable, convertible debentures and convertible promissory notes approximate fair value since each of these investments are at market rates currently available to the Company.
	Long-Lived Assets
	The Company reviews its long-lived assets, which include property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with Accounting Standards Codification (“ASC”) 360-10-35-15, “Property, Plant and Equipment-Impairment or Disposal of Long-Lived Assets.”  Recoverability of these assets is evaluated by comparing the carrying value of the assets to the undiscounted cash flows estimated to be generated by the assets over their remaining economic life.  If the undiscounted cash flows are not sufficient to recover the carrying value of the assets, the assets are considered impaired.  The impairment loss is measured by comparing the fair value of the assets to their carrying value.  Fair value is determined by either a quoted market price, if any, or a value determined by a discounted cash flow technique.  There were no material impairment charges related to the Company’s property and equipment during the years ended December 31, 2013 or 2012.
	Revenue Recognition
	General
	Revenue is recognized when persuasive evidence of an arrangement exists, title and risk of ownership have passed, the sales price is fixed or determinable and collectability is probable.  Generally, these criteria are met at the time the product is shipped.  Provisions for estimated returns, rebates and discounts are provided for at the time the related revenue is recognized.  Freight revenue billed to customers is included in sales and the related shipping expense is included in cost of sales.  Service revenue is recognized in the period the service is performed or ratably over the period of the related service contract.
	Leases
	When the Company leases its equipment, the accounting involves specific determinations, which often involve complex provisions and significant judgments.  The four criteria of the accounting standard that the Company uses in the determination of a sales-type lease or operating-type lease are: (a) a review of the lease term to determine if it is equal to or greater than 75% of the economic life of the equipment; (b) a review of the minimum lease payments to determine if they are equal to or greater than 90% of the fair market value of the equipment; (c) a determination of whether or not the lease transfers ownership to the lessee at the end of the lease term; and (d) a determination of whether or not the lease contains a bargain purchase option.  If the lease transaction meets one of the four criteria, then it is recorded as a sales-type lease; otherwise, it is recorded as an operating-type lease.  Additionally, the Company assesses whether collectability of the lease payments is reasonably assured and whether there are any significant uncertainties related to costs that it has yet to incur with respect to the lease.
	When a customer enters into a sales-type lease agreement, the sales and cost of sales are recognized at the inception of the lease.  The sales-type lease consists of the sum of the total minimum lease payments less unearned interest income and estimated executory cost.  Minimum lease payments are part of the lease agreement between the Company (lessor) and the customer (lessee).  The discount rate implicit in the sales-type lease is used to calculate the present value of minimum lease payments, which the Company records as a lease receivable.  The minimum lease payment consists of the gross lease payments net of executory costs and contingencies, if any.  Unearned interest income is amortized over the lease term to produce a constant periodic rate of return on net investment in the lease.  While revenue is recognized at the inception of the lease, the cash flow from the sales-type lease occurs over the course of the lease, which results in interest income.  Sales-type lease revenue consists of the initial sale of the equipment shipped and the interest and license elements of the lease payments as they are earned.
	When a customer enters into an operating-type lease agreement, equipment lease revenue is recognized on a straight-line basis over the life of the lease, while the cost of the leased equipment is depreciated over its estimated useful life.
	Income Taxes
	The Company accounts for income taxes under ASC 740, “Income Taxes” (“ASC 740”).  ASC 740 requires that the Company recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carry-forwards to the extent they are realizable.  The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.  While the Company has considered future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance, in the event the Company was to determine that it would be able to realize the deferred tax assets in the future in excess of the net recorded amount, an adjustment to the deferred tax asset would increase income in the period such determination was made.  Likewise, deferred tax assets are reduced by a valuation allowance, when in the Company’s opinion, it is more likely than not that some portion or all of the deferred tax asset will not be realized.
	Research and Development
	The Company expenses research and development costs as incurred.
	Stock-Based Compensation
	The Company accounts for stock-based payments to employees in accordance with ASC 718, “Stock Compensation” (“ASC 718”).  Stock-based payments to employees include issuances of stock, grants of stock options and issuance of warrants that are recognized in the consolidated statement of operations based on their fair values at the date of grant or issuance.
	The Company accounts for stock-based payments to non-employees in accordance with ASC 718 and Topic 505-50, “Equity-Based Payments to Non-Employees.”  Stock-based payments to non-employees include issuances of stock, grants of stock options and issuances of warrants that are recognized in the consolidated statement of operations based on the value of the vested portion of the award over the requisite service period as measured at its then-current fair value as of each financial reporting date.
	The Company calculates the fair value of option grants and warrant issuances utilizing the Black-Scholes pricing model.  The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.  ASC 718 requires forfeitures to be estimated at the time stock options are granted and warrants are issued to employees and non-employees, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant.  The Company estimates forfeiture rates for all unvested awards when calculating the expense for the period.  In estimating the forfeiture rate, the Company monitors both stock option and warrant exercises as well as employee termination patterns.
	The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.
	During the years ended December 31, 2013 and 2012, the Company recorded stock-based compensation expense as follows:
			Year Ended
			December 31,
			2013		2012
	General and administrative		$	90,969	$	79,485
	Sales and marketing			10,220		65,674
	Research and development			4,380		19,380
	Total		$	105,569	$	164,539
	For the years ended December 31, 2013 and 2012, the Company recorded stock-based compensation expense related to stock options granted to employees and directors of $48,607 and $144,084, respectively.  For the years ended December 31, 2013 and 2012, the Company recorded stock-based compensation expense related to common stock and warrants issued to non-employees of $56,962 and $20,455, respectively.
	Net Loss Per Common Share
	Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive.  The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.
	For the year ended December 31, 2013, diluted net loss per share did not include the effect of 4,980,254 shares of common stock issuable upon the exercise of outstanding stock options, 36,844,565 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debentures, as their effect would be anti-dilutive.
	For the year ended December 31, 2012, diluted net loss per share did not include the effect of 5,813,587 shares of common stock issuable upon the exercise of outstanding stock options, 45,852,998 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debentures, as their effect would be anti-dilutive.
	Reclassifications
	Certain reclassifications have been made to prior periods to conform to current presentations.
	Recent Accounting Pronouncements Applicable to the Company
	The Company does not believe there are any recently issued, but not yet effective, accounting standards that would have a significant impact on the Company’s financial position or results of operations.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
Inventory	'
	4.	Inventory
	As of December 31, 2013 and December 31, 2012, inventory consisted of parts and materials totaling $126,952 and $82,566, respectively.
	During March 2013 and December 2012, the Company reclassified $17,487 and $138,336, respectively, of EcaFlo™ equipment from finished goods inventory to property and equipment.  The Company no longer intends to sell its EcaFlo™ equipment but rather will either utilize the EcaFlo™ equipment to manufacture Anolyte and Catholyte solutions to be sold by the Company or lease the EcaFlo™ equipment to third parties.

Note_Receivable

Note Receivable	12 Months Ended
	Dec. 31, 2013
Lease and Note Receivables [Abstract]	'
Note Receivable	'
	5.	Note Receivable
	The Company had a note receivable with a customer relating to the sale of certain EcaFlo™ equipment.  The note payments were $1,250 per month over a 34-month term which commenced on January 15, 2011.  The Company imputed interest on this note receivable at a rate of 3% per annum.
	During the years ended December 31, 2013 and 2012, the Company and the customer agreed to apply $4,172 and $6,414, respectively, of accounts payable due by the Company to the customer against the note receivable balance due from the customer to the Company.  The accounts payable amounts due by the Company to the customer related to the purchase of certain parts and materials by the Company from the customer.  As of December 31, 2013 and 2012, the outstanding balance of the note receivable was $0 and $7,762, respectively.
	During the years ended December 31, 2013 and 2012, the Company recognized $74 and $714, respectively, of interest income related to this note receivable.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
Property and Equipment	'
	6.	Property and Equipment
	As of December 31, 2013 and 2012, property and equipment, on a net basis, consisted of the following (see Note 4):
			Year Ended
			December 31,
			2013			2012
	Leasehold improvements		$	328,977		$	328,977
	Equipment			437,504			203,368
				766,481			532,345
	Less:  Accumulated depreciation			(421,597	)		(249,363	)
			$	344,884		$	282,982

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	7.	Accrued Expenses
	As of December 31, 2013 and December 31, 2012, accrued expenses consisted of the following:
			Year Ended
			December 31,
			2013		2012
	Accrued compensation		$	--	$	115,000
	Accrued interest			24,321		21,330
	Accrued auditing fees			22,000		22,000
	Accrued other expenses			1,633		1,633
			$	47,954	$	159,963

Customer_Deposits

Customer Deposits	12 Months Ended
	Dec. 31, 2013
Customer Deposits [Abstract]	'
Customer Deposits	'
	8.	Customer Deposits
	On March 29, 2011, the Company issued a credit to purchase equipment to a consultant in the amount of $36,109 as payment to the consultant for consulting services rendered to the Company.  The Company has recorded this amount as a customer deposit.
	Effective January 1, 2013, the Company entered into a license agreement with a third party related to the use by the third party of the Company’s United States Environmental Protection Agency (the “EPA”) registration for its Anolyte solution.  The Company received a deposit of $2,000 pursuant to the terms of this agreement.

Convertible_Debentures

Convertible Debentures	12 Months Ended
	Dec. 31, 2013
Convertible Debentures [Abstract]	'
Convertible Debentures	'
	9.	Convertible Debentures
	April 2007 Convertible Debenture
	On April 26, 2007, in a private placement, the Company issued a convertible debenture to an individual accredited investor in the principal amount of $25,000.  This convertible debenture matured on January 2, 2009 and remains unpaid.  The convertible debenture accrues interest at a rate of 12% per annum and is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.40 per share.  An aggregate of 62,500 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on this convertible debenture at the current conversion price of $0.40 per share.
	During the years ended December 31, 2013 and 2012, the Company recorded a total of $2,992 and $3,008, respectively, of interest expense related to this convertible debenture.  As of December 31, 2013 and 2012, the outstanding principal on this convertible debenture was $25,000 and the accrued and unpaid interest was $10,441 and $7,450, respectively, which is included as a component of accrued expenses.
	Zanett Convertible Debentures
	On August 21, 2012, the Company issued to Zanett Opportunity Fund, Ltd. (“Zanett”) an 8% convertible debenture in the amount of $476,125 (the “Zanett August 2012 Debenture”).  In connection with this private placement, the Company refinanced an 8% convertible debenture, in the principal amount of $376,125, issued to Zanett on July 7, 2011 (the “Zanett July 2011 Debenture”) and refinanced an 8% convertible secured promissory note, in the principal amount of $100,000, issued to Zanett on September 23, 2011 (see Note 10).  As a result of the issuance of the Zanett August 2012 Debenture, the Zanett July 2011 Debenture and the 8% convertible secured promissory note issued to Zanett were cancelled.
	The Zanett August 2012 Debenture has a three-year term maturing on August 21, 2015 and bears interest at a rate of 8% per annum.  Interest is payable in annual installments in cash or, at the option of the Company, in shares of the Company’s common stock.  If the Company elects to pay the interest in shares of its common stock, the number of shares issued as payment will be equal to the quotient of the unpaid interest divided by the market price of the Company’s common stock, as defined in the Zanett August 2012 Debenture.
	The entire principal amount of the Zanett August 2012 Debenture is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.10 per share.  In addition, at the option of the Company, the entire principal amount of the Zanett August 2012 Debenture is convertible into shares of the Company’s common stock at $0.10 per share upon the occurrence of the merger or acquisition of the Company or if the average closing price of the Company’s common stock for any period of ten consecutive trading days is greater than or equal to $0.15 per share.  The quoted market price of the Company’s common stock on August 21, 2012 was $0.05 per share.  An aggregate of 4,761,250 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on the Zanett August 2012 Debenture at the current conversion price of $0.10 per share.
	On August 21, 2012, the Company issued 491,690 shares of the Company’s common stock to Zanett as payment of $33,800 of accrued interest due on the Zanett July 2011 Debenture for the period commencing July 7, 2011 through August 21, 2012.  The number of shares of the Company’s common stock issued as payment of the accrued interest was calculated based on the market price of the Company’s common stock ($0.07 per share for the period commencing July 7, 2011 through July 6, 2012 and $0.06 per share for the period commencing July 7, 2012 through August 21, 2012) as defined in the Zanett July 2011 Debenture.
	On August 22, 2013, the Company issued 400,947 shares of the Company’s common stock to Zanett as payment of $38,090 of accrued interest due on the Zanett August 2012 Debenture for the period commencing August 21, 2012 through August 20, 2013.  The number of shares of the Company’s common stock issued as payment of the accrued interest was calculated based on the market price of the Company’s common stock ($0.095 per share) as defined in the Zanett August 2012 Debenture.
	For the year ended December 31, 2013, the Company recorded $38,090 of interest expense related to the Zanett August 2012 Debenture.  For the year ended December 31, 2012, the Company recorded $32,802 of interest expense related to the Zanett July 2011 Debenture and the Zanett August 2012 Debenture.
	As of December 31, 2013 and 2012, the outstanding principal on the Zanett August 2012 Debenture was $476,125 and the accrued and unpaid interest was $13,880, which is included as a component of accrued expenses.
	Kinsey Convertible Debenture
	On July 7, 2011, in a private placement, the Company issued to E. Wayne Kinsey, III, a member of the Company’s board of directors, an 8% convertible debenture in the amount of $150,000 (the “Kinsey Debenture”).  The Kinsey Debenture had a three-year term that was due to mature on July 7, 2014, and accrued interest at a rate of 8% per annum.
	On August 17, 2012, the Company issued to Mr. Kinsey 1,500,000 shares of the Company’s common stock in connection with Mr. Kinsey’s election to convert the entire outstanding principal amount of the Kinsey Debenture.  Pursuant to the terms of the Kinsey Debenture, the outstanding principal was converted into shares of the Company’s common stock at $0.10 per share.  As a result of this conversion, the Kinsey Debenture was cancelled.
	On August 17, 2012, the Company issued 193,895 shares of the Company’s common stock as payment of $13,348 of accrued interest due on the Kinsey Debenture for the period commencing July 7, 2011 through August 16, 2012.  The number of shares of the Company’s common stock issued as payment of the accrued interest was calculated based on the quoted market price of the Company’s common stock ($0.07 per share for the period commencing July 7, 2011 through July 6, 2012 and $0.06 per share for the period commencing July 7, 2012 through August 16, 2012), as defined in the Kinsey Debenture.
	For the year ended December 31, 2012, the Company recorded $7,414 of interest expense related to the Kinsey Debenture.

Note_Payable

Note Payable	12 Months Ended
	Dec. 31, 2013
Note Payable [Abstract]	'
Debt Disclosure [Text Block]	'
	10.	Note Payable
	On June 17, 2013, the Company and Benchmark Performance Group, Inc. (“Benchmark”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), whereby the Company purchased nineteen EcaFlo™ machines owned by Benchmark as well as the rights to the Excelyte™ trademark and certain other intangible assets.  The purchase price for the nineteen EcaFlo™ machines, the Excelyte™ trademark and other intangible assets was $190,000.
	The Company paid $38,000 in conjunction with the closing of the Asset Purchase Agreement and issued a promissory note with a principal balance of $152,000 (the “Benchmark Note”).  The Benchmark Note bears interest at a rate of 7% per annum and requires the Company to make twenty-four monthly payments of $6,805 commencing August 1, 2013.  The Benchmark Note is secured by the nineteen EcaFlo™ machines.
	For the year ended December 31, 2013, the Company recorded $4,086 of interest expense related to the Benchmark Note.  As of December 31, 2013, the outstanding principal on the Benchmark Note was $122,059 (current portion:  $75,513; long-term portion:  $46,546).

Convertible_Promissory_Notes

Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Notes [Abstract]	'
Convertible Promissory Notes	'
	11.	Convertible Promissory Notes
	On September 23, 2011, the Company, E. Wayne Kinsey, III, a member of the Company’s board of directors, and Zanett entered into a note purchase agreement, pursuant to which Mr. Kinsey purchased an 8% convertible secured promissory note from the Company in the principal amount of $400,000 (the “Kinsey Secured Note”) and Zanett purchased an 8% convertible secured promissory note from the Company in the principal amount of $100,000 (the “Zanett Secured Note”).
	In connection with the execution of the note purchase agreement and the issuance of the Kinsey Secured Note and the Zanett Secured Note, the Company provided certain registration rights to each holder.  In the event that the Company proposes to register shares of its common stock under the Securities Act of 1933, as amended, under certain circumstances, Mr. Kinsey and Zanett will be allowed to include shares of the Company’s common stock held by them in such registration.  The Company determined that the value attributable to these registration rights was de minimis.
	On August 17, 2012, the Company issued to Mr. Kinsey 4,000,000 shares of the Company’s common stock in connection with Mr. Kinsey’s election to convert the Kinsey Secured Note.  Pursuant to the terms of the Kinsey Secured Note, the outstanding principal was converted into shares of the Company’s common stock at $0.10 per share.  As a result of this conversion, the Kinsey Secured Note was cancelled.
	On August 17, 2012, the Company issued 480,733 shares of the Company’s common stock to Mr. Kinsey as payment of $28,844 of accrued interest due on the Kinsey Secured Note for the period commencing September 23, 2011 through August 16, 2012.  The number of shares of the Company’s common stock issued as payment of the accrued interest was calculated based on the quoted market price of the Company’s common stock ($0.06 per share) as defined in the Kinsey Secured Note.
	On August 21, 2012, in connection with the issuance of the Zanett August 2012 Debenture, the Company refinanced the Zanett Secured Note and the Zanett Secured Note was cancelled (see Note 9).
	As a result of the cancellation of both the Kinsey Secured Note and the Zanett Secured Note, the collateral securing the notes was released.
	On August 21, 2012, the Company issued 122,017 shares of the Company’s common stock to Zanett as payment of $7,321 of accrued interest due on the Zanett Secured Note for the period commencing September 23, 2011 through August 21, 2012.  The number of shares of the Company’s common stock issued as payment of the accrued interest was calculated based on the market price of the Company’s common stock ($0.06 per share) as defined in the Zanett Secured Note.
	For the year ended December 31, 2012, the Company recorded a total of $25,316 of interest expense related to the Kinsey Secured Note and the Zanett Secured Note.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	12.           Income Taxes
	The difference between the statutory federal income tax rate on the Company’s pre-tax loss and the Company’s effective income tax rate is summarized as follows:
		Years Ended
		December 31,						December 31,
		2013						2012
		Amount			Percent			Amount			Percent
	Income tax provision at federal statutory rate	$	(622,626	)		34	%	$	(654,669	)		34	%
	Effect of state taxes, net of federal benefit		(54,938	)		3			(57,765	)		3
	Change in valuation allowance		679,700			(37	)		712,367			(37	)
	Other		(2,136	)		--			67			--
		$	--			--	%	$	--			--	%
	Significant components of the Company’s deferred tax assets as of December 31, 2013 and 2012 are shown below.  In determining whether the deferred tax assets will be realized, the Company considered numerous factors, including historical profitability, estimated future taxable income and the industry in which it operates.  As of December 31, 2013 and 2012, a valuation allowance was recorded to fully offset the net deferred tax asset, as it was determined by management that the realization of the deferred tax asset was not likely to occur in the foreseeable future.  The valuation allowance increased $679,700 during the year ended December 31, 2013, attributable primarily to Company’s continuing operating losses for the year ended December 31, 2013 and the Company’s belief that its remaining net operating losses would not be realized.
	The tax effects of temporary differences and net operating loss carry-forwards that give rise to deferred taxes consist of the following:
		Years Ended
		December 31,
		2013			2012
	Net operating loss	$	6,710,397		$	6,105,330
	Depreciation and amortization		53,604			--
	Stock based compensation		309,208			286,075
	Total gross deferred tax assets		7,073,209			6,391,405
	Valuation allowance		(7,073,209	)		(6,391,405	)
	Net deferred tax assets	$	--		$	--
	As of December 31, 2013, the Company had federal and state operating losses of approximately $17,990,000.  Both the federal and state operating losses begin to expire in the years 2021 through 2033.
	Utilization of the net operating loss carry-forwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), and similar state provisions.  The Company has not performed a detailed analysis to determine whether an ownership change under Section 382 of the Internal Revenue Code occurred.  The effect of an ownership change would be the imposition of an annual limitation on the use of net operating loss carry-forwards attributable to periods before the change.
	The Company’s 2010, 2011 and 2012 federal and state income tax returns are open for examination by the applicable governmental authorities.

Stockholders_Equity_Deficiency

Stockholders' Equity (Deficiency)	12 Months Ended
	Dec. 31, 2013
Stockholders' Deficiency [Abstract]	'
Stockholders' Deficiency	'
	13.	Stockholders’ Equity (Deficiency)
	Common Stock and Common Stock Units
	On January 24, 2012, the Company sold, to an institutional investor, common stock units that in aggregate consisted of 8,750,000 shares of the Company’s common stock and a warrant to purchase 8,750,000 shares of the Company’s common stock, for an aggregate purchase price of $700,000, or $0.08 per share.  The warrant has a three-year term, is exercisable at $0.10 per share and was fully vested at the date of issuance.  The Company incurred offering costs of $70,000 in connection with this transaction.
	On February 2, 2012, the Company sold, to an institutional investor, common stock units that in aggregate consisted of 3,125,000 shares of the Company’s common stock and a warrant to purchase 1,562,500 shares of the Company’s common stock, for an aggregate purchase price of $250,000, or $0.08 per share.  The warrant has a three-year term, is exercisable at $0.20 per share and was fully vested at the date of issuance.  The Company incurred offering costs of $17,500 in connection with this transaction.
	On February 28, 2012, the Company sold, to an individual accredited investor, common stock units that in aggregate consisted of 375,000 shares of the Company’s common stock and a warrant to purchase 187,500 shares of the Company’s common stock, for an aggregate purchase price of $30,000, or $0.08 per share.  The warrant has a three-year term, is exercisable at $0.20 per share and was fully vested at the date of issuance.  The Company incurred offering costs of $2,100 in connection with this transaction.
	On March 27, 2012, the Company issued 10,000 shares of the Company’s common stock as payment for services rendered to the Company by an unaffiliated third party.  The total expense associated with the issuance of these shares was $800, representing the fair market value of the shares based on the quoted market price of the Company’s common stock on the date the issuance was authorized ($0.08 per share on March 2, 2012).
	On March 27, 2012, the Company issued an aggregate of 360,000 shares of the Company’s common stock to certain of its directors as payment of $36,000 of director fees due for services rendered in fiscal 2011.  The aggregate fair market value of these shares, based on the quoted market price of the Company’s common stock on the date of issuance ($0.05 per share), was $18,000.  The Company recorded the difference between the total payment owed ($36,000) and the fair market value of the common stock issued ($18,000) as additional paid-in capital.
	On June 19, 2012, the Company sold, to an institutional investor, common stock units that in aggregate consisted of 1,875,000 shares of the Company’s common stock and a warrant to purchase 937,500 shares of the Company’s common stock, for an aggregate purchase price of $150,000, or $0.08 per share.  The warrant has a three-year term, is exercisable at $0.20 per share and was fully vested at the date of issuance.  The Company incurred offering costs of $10,500 in connection with this transaction.
	On August 17, 2012, the Company sold to E. Wayne Kinsey, III, a member of the Company’s board of directors, common stock units that in aggregate consisted of 6,250,000 shares of the Company’s common stock and a warrant to purchase 3,125,000 shares of the Company’s common stock, for an aggregate purchase price of $500,000, or $0.08 per share.  The warrant has a three-year term, is exercisable at $0.20 per share and was fully vested at the date of issuance.  The quoted market price of the Company’s common stock on the date of closing this transaction was $0.05 per share.
	On December 7, 2012, the Company issued 100,000 shares of the Company’s common stock as payment for services rendered to the Company by an unaffiliated third party.  The total expense associated with the issuance of these shares was $5,000, representing the fair market value of the shares based on the quoted market price of the Company’s common stock on the date the issuance was authorized ($0.05 per share on December 7, 2012).
	On February 4, 2013, the Company issued an aggregate of 1,485,714 shares of the Company’s common stock, at a per share price of $0.035, as settlement of $52,000 of fees due to certain members of the Company’s board of directors for services rendered during the year ended December 31, 2012.  The quoted market price of the Company’s common stock on the date the issuance was approved by the Company’s board of directors was $0.035 per share.
	On February 12, 2013, the Company sold to E. Wayne Kinsey III, a member of the Company’s board of directors, 4,166,667 shares of the Company’s common stock for an aggregate purchase price of $125,000, or $0.03 per share.  The $0.03 per share price was the same price offered to other non-affiliated investors in a private placement of the Company’s common stock.  In addition, the Company sold 3,333,333 shares of its common stock to an institutional investor for an aggregate purchase price of $100,000, or $0.03 per share, and incurred offering costs of $7,000 in connection with this sale of common stock.
	On February 28, 2013, the Company issued 250,000 shares of its common stock in connection with a consulting agreement with an unaffiliated third party for investor relations services.  The total expense associated with the issuance of these shares was $9,125, representing the fair market value of the shares of common stock on the date of issuance ($0.0365 per share).
	On March 1, 2013, the Company sold 2,500,000 shares of its common stock to an institutional investor for an aggregate purchase price of $75,000, or $0.03 per share.  The Company incurred offering costs of $5,250 in connection with this sale of common stock.
	On March 22, 2013, the Company sold 800,000 shares of its common stock to an individual investor for an aggregate purchase price of $24,000, or $0.03 per share.
	On March 31, 2013, the Company issued 250,000 shares of its common stock in connection with a consulting agreement with an unaffiliated third party for investor relations services.  The total expense associated with the issuance of these shares was $10,050, representing the fair market value of the shares of common stock on the date of issuance ($0.042 per share).
	On April 30, 2013, the Company sold to E. Wayne Kinsey III, a member of the Company’s board of directors, 4,166,667 shares of the Company’s common stock for an aggregate purchase price of $125,000, or $0.03 per share.  The $0.03 per share price was the same price offered to other non-affiliated investors in a private placement of the Company’s common stock.  In addition, the Company sold 3,000,000 shares of its common stock to an individual investor for an aggregate purchase price of $90,000, or $0.03 per share.
	On April 30, 2013, the Company issued 250,000 shares of its common stock in connection with a consulting agreement with an unaffiliated third party for investor relations services.  The total expense associated with the issuance of these shares was $11,875, representing the fair market value of the shares of common stock on the date of issuance to the consultant ($0.0475 per share).
	On May 16, 2013, the Company sold an aggregate of 2,666,666 shares of its common stock to four individual investors for an aggregate purchase price of $80,000, or $0.03 per share.
	On May 22, 2013, the Company sold 3,333,333 shares of its common stock to an individual investor for an aggregate purchase price of $100,000, or $0.03 per share.
	On May 31, 2013, the Company issued 250,000 shares of its common stock in connection with a consulting agreement with an unaffiliated third party for investor relations services.  The total expense associated with the issuance of these shares was $12,500, representing the fair market value of the shares of common stock on the date of issuance to the consultant ($0.05 per share).
	On June 20, 2013, the Company sold 800,000 shares of its common stock to an individual investor for an aggregate purchase price of $24,000, or $0.03 per share.
	On June 26, 2013, the Company issued 450,000 shares of its common stock to Crystal Enterprises, Inc. (“Crystal”) in order to resolve certain disputes and to avoid further litigation costs associated with defending litigation brought by Crystal (see Note 15).  The total expense associated with the issuance of these shares was $26,550, representing the fair market value of the shares of common stock on the date of issuance to Crystal ($0.059 per share).
	On June 28, 2013, the Company sold 850,000 shares of its common stock to an individual investor for an aggregate purchase price of $25,500, or $0.03 per share.
	On July 11, 2013, the Company sold an aggregate of 2,400,000 shares of its common stock to two individual investors for an aggregate purchase price of $72,000, or $0.03 per share.
	On July 31, 2013, the Company sold an aggregate of 7,366,665 shares of its common stock to eleven individual investors for an aggregate purchase price of $221,000, or $0.03 per share.  The Company incurred offering costs of $11,740 in connection with these transactions.
	On August 2, 2013, the Company sold an aggregate of 2,803,366 shares of its common stock to six individual investors for an aggregate purchase price of $84,101, or $0.03 per share.  The Company incurred offering costs of $5,808 in connection with these transactions.
	On August 5, 2013, the Company sold 3,333,333 shares of its common stock to an institutional investor and 500,000 shares of its common stock to an individual investor for an aggregate purchase price of $115,000, or $0.03 per share.  The Company incurred offering costs of $8,050 in connection with these transactions.
	On August 9, 2013, the Company sold an aggregate of 4,833,333 shares of its common stock to nine individual investors for an aggregate purchase price of $145,000, or $0.03 per share.  The Company incurred offering costs of $9,100 in connection with these transactions.
	On August 16, 2013, the Company sold an aggregate of 6,803,333 shares of its common stock to nine individual investors for an aggregate purchase price of $204,100, or $0.03 per share.  The Company incurred offering costs of $9,587 in connection with these transactions.
	On August 23, 2013, the Company sold 1,700,000 shares of its common stock to an institutional investor and 1,533,333 shares of its common stock to four individual investors for an aggregate purchase price of $97,000, or $0.03 per share.  The Company incurred offering costs of $5,460 in connection with these transactions.
	On August 30, 2013, the Company sold 1,000,000 shares of its common stock to an individual investor for an aggregate purchase price of $30,000, or $0.03 per share.  The Company incurred offering costs of $2,100 in connection with this transaction.
	On September 13, 2013, the Company issued an aggregate of 228,125 shares of the Company’s common stock, at a per share price of $0.08, as settlement of $18,250 of fees due certain members of the Company’s board of directors for services rendered for the period commencing January 1, 2013 through August 31, 2013.  The quoted market price of the Company’s common stock on the date the issuance was approved by the Company’s board of directors was $0.08 per share.
	On November 5, 2013, the Company sold 1,000,000 shares of its common stock to an individual investor for an aggregate purchase price of $66,000, or $0.066 per share.  The Company issued 100,000 shares of its common stock to an unaffiliated third party as payment of $6,600 of offering costs related to this transaction.
	On November 7, 2013, the Company sold 15,151,515 shares of its common stock to an individual investor for an aggregate purchase price of $1,000,000, or $0.066 per share.  The Company issued 1,515,152 shares of its common stock to an unaffiliated third party as payment of $100,000 of offering costs related to this transaction.
	On November 13, 2013, the Company sold 347,222 shares of its common stock to an individual investor for an aggregate purchase price of $25,000, or $0.072 per share. The Company issued 34,722 shares of its common stock to an unaffiliated third party as payment of $2,500 of offering costs related to this transaction.
	Stock Options
	Stock Option Plans
	The Company currently has two stock option/stock compensation plans in place:  the 2010 Stock Incentive Plan and the 2012 Equity Incentive Plan (collectively, the “Equity Incentive Plans”).
	The 2010 Stock Incentive Plan was approved by the stockholders in September 2010.  The Company had reserved for issuance an aggregate of 10,000,000 shares of common stock under the 2010 Stock Incentive Plan.  As of December 31, 2013, stock options to purchase 4,980,254 shares of the Company’s common stock were outstanding under the 2010 Stock Incentive Plan and 90,500 shares of the Company’s common stock had been issued under the 2010 Stock Incentive Plan.  As a result of the adoption of the Company’s 2012 Equity Incentive Plan, no further awards are permitted under the 2010 Stock Incentive Plan.
	The 2012 Equity Incentive Plan was approved by the stockholders in May 2012.  The Company has reserved for issuance an aggregate of 14,000,000 shares of common stock under the 2012 Stock Incentive Plan.  The 2012 Equity Incentive Plan is designed to encourage and enable employees and directors of the Company to acquire or increase their holdings of common stock and other proprietary interests in the Company.  It is intended to promote these individuals’ interests in the Company, thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company.  The 2012 Equity Incentive Plan provides for grants and/or awards in the form of incentive and non-qualified stock option grants, stock appreciation rights, restricted stock awards, performance share awards, phantom stock awards and dividend equivalent awards.  As of December 31, 2013, no grants or awards had been made under the 2012 Equity Incentive Plan.
	Common stock grants and stock option awards under the Equity Incentive Plans were granted or issued at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company's common stock on the date of grant or issuance.  Stock options granted and outstanding to date consist of both incentive stock options and non-qualified stock options.
	Stock Option Transactions
	Stock Options Issued to Executive Officers – March 2012
	On March 27, 2012, the Company granted incentive stock options to purchase an aggregate of 5,000,000 shares of the Company’s common stock under the 2010 Stock Incentive Plan to the Company’s executive officers as follows:  David R. LaVance, President and Chief Executive Officer – 3,000,000 shares, and Thomas S. Gifford, Executive Vice President and Chief Financial Officer – 2,000,000 shares.  On December 31, 2012, an aggregate of 833,333 shares of common stock underlying the incentive stock options (500,000 shares for Mr. LaVance and 333,333 shares for Mr. Gifford), with an exercise price of $0.10 per share, were terminated as a result of the Company’s failure to attain breakeven operating results, as defined in the incentive stock option agreements, for a period of four consecutive months or two consecutive quarters during the year ended December 31, 2012.    On December 31, 2013, an aggregate of 833,333 shares of common stock underlying the incentive stock options (500,000 shares for Mr. LaVance and 333,333 shares for Mr. Gifford), with an exercise price of $0.20 per share, were terminated as a result of the Company’s failure to attain at least $5,000,000 of revenues for the twelve month period ended December 31, 2013.    The remaining 3,333,334 shares of common stock underlying the incentive stock options vest or vested, in aggregate, as follows:  833,333 shares vested on December 31, 2012, 833,333 shares vested on December 31, 2013 and 833,334 vest on December 31, 2014 and may be purchased at a per share exercise price of $0.10, $0.20 and $0.30, respectively; and 833,334 shares vest upon the Company achieving at least $10,000,000 of revenues for the twelve-month period ending December 31, 2014 and may be purchased at a per share exercise price of $0.30 per share.
	Each of the incentive stock options has a ten-year term, and in the event of a change in control of the Company, as defined in the 2010 Stock Incentive Plan, the incentive stock options become fully vested.  The aggregate fair value of the incentive stock options on the date of grant not subject to performance measures that will be earned over the requisite service period, as calculated using the Black-Scholes model, was $80,812, using the following weighted average assumptions:  exercise price of $0.20 per share; common stock price of $0.05 per share; volatility of 187%; term of ten years; dividend yield of 0%; interest rate of 2.29%; and risk of forfeiture of 35%.  This amount is being expensed on a pro-rata basis over the requisite service period.
	Stock Options Issued to Non-Executive Directors
	On March 27, 2012, the Company granted non-qualified stock options to purchase an aggregate of 1,346,920 shares of the Company’s common stock under the 2010 Stock Incentive Plan to the non-executive members of the Company’s board of directors as follows:  Raymond C. Kubacki – 541,860 shares; David N. Harry – 309,640 shares; Valgene L. Dunham – 340,600 shares; and E. Wayne Kinsey, III – 154,820 shares.  The options were granted as partial consideration for each person’s continuing service in 2012 as a member of the Company’s board of directors and related committees.  Each of the options has a five-year term and is exercisable at $0.10 per share.  The shares of common stock underlying the options, in aggregate, vested as follows:  673,460 shares vested on December 31, 2012 and 673,460 shares vested on December 31, 2013.
	The aggregate fair value of the options on the date of grant as calculated using the Black-Scholes model was $37,530, using the following weighted average assumptions:  exercise price of $0.10 per share; common stock price of $0.05 per share; volatility of 145%; term of five years; dividend yield of 0%; interest rate of 1.13%; and risk of forfeiture of 35%.  The fair value of the option grants is being expensed on a pro-rata basis over the requisite service period.
	A summary of stock option transactions under the Equity Incentive Plans during the years ended December 31, 2013 and 2012 is set forth below:
			Stock				Weighted				Aggregate
			Option				Average				Intrinsic
			Shares				Exercise				Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2011			300,000			$	0.08			$	--
	Granted during the period			6,346,920				0.18
	Exercised during the period			--				--
	Terminated during the period			(833,333	)		$	0.1
	Outstanding at December 31, 2012			5,813,587			$	0.18			$	--
	Granted during the period			--				0.18
	Exercised during the period			--				--
Terminated during the period			(833,333	)		$	0.2
Outstanding at December 31, 2013			4,980,254			$	0.18			$	55,605
Exercisable at December 31, 2013			3,313,586			$	0.12			$	42,136
Exercisable at December 31, 2012			1,806,793			$	0.1			$	--
Information with respect to outstanding stock options and stock options exercisable as of December 31, 2013 that were granted to employees, directors and service providers is as follows:
				Stock Options Outstanding										Stock Options Exercisable
Exercise				Number of				Weighted				Weighted		Number of		Weighted		Weighted
Price				Shares				Average				Average		Shares		Average		Average
				Available				Exercise				Remaining		Available for		Exercise		Remaining
				Under				Price Per				Contractual		Purchase		Price Per		Contractual
				Outstanding				Common				Life (Years)		Under		Common Share		Life (Years)
				Stock				Share						Outstanding
				Options										Stock
														Options
$	0.08				300,000			$	0.08				0.3		300,000	$	0.08		0.3
$	0.1				2,180,253			$	0.1				5.2		2,180,253	$	0.1		5.2
$	0.2				833,333			$	0.2				8.3		833,333	$	0.2		8.3
$	0.3				1,666,668			$	0.3				8.3		--		--		--
					4,980,254			$	0.18				6.4		3,313,586	$	0.12		5.5
A summary of the non-vested shares subject to options granted under the Equity Incentive Plans as of December 31, 2013 and 2012 is as follows:
		Stock				Weighted
		Option Shares				Average
						Grant Date
						Fair Value
						Per Share
Non-vested at December 31, 2011			--				--
Granted during the period			6,346,920			$	0.05
Vested during the period			(1,506,793	)		$	0.05
Terminated during the period			(833,333	)		$	0.05
Non-vested at December 31, 2012			4,006,794			$	0.05
Granted during the period			--				--
Vested during the period			(1,506,793	)		$	0.05
Terminated during the period			(833,333	)		$	0.05
Non-vested at December 31, 2013			1,666,668			$	0.05
As of December 31, 2013, there was $32,451 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Equity Incentive Plans.  That cost is expected to be recognized over a weighted average period of eleven months.
Warrants to Purchase Common Stock
On May 23, 2011, the Company issued warrants to purchase a total of 6,200,000 shares of the Company’s common stock to its executive officers.  David R. LaVance, the Company’s Chairman, President and Chief Executive Officer, was issued a warrant to purchase 3,100,000 shares of the Company’s common stock and Thomas S. Gifford, the Company’s Executive Vice President, Chief Financial Officer and Secretary, also was issued a warrant to purchase 3,100,000 shares of the Company’s common stock.  These warrants are exercisable at $0.09 per share for a term of ten years and are fully vested.  The fair value of the warrants on the date of issuance as calculated using the Black-Scholes model was $349,520, using the following weighted average assumptions:  exercise price of $0.09 per share; common stock price of $0.09 per share; volatility of 130%; term of ten years; dividend yield of 0%; interest rate of 1.83%; and risk of forfeiture of 35%.  This amount was recognized as an expense over the eighteen-month vesting period of the warrants.
On December 6, 2011, the Company issued warrants to purchase an aggregate of 2,000,000 shares of the Company’s common stock to TrueLogix, LLC, Colby J. Sanders, Patrick T. Lewis and Howard B. Gee pursuant to a Sales Management Services Agreement (the “Sales Management Agreement”) entered into by the parties on December 6, 2011 (see Note 15 – Commitments and Contingencies:  TrueLogix Sales Management Agreement).  The warrants have a three-year term and are exercisable at $0.20 per share.  On September 21, 2012, as a result of the termination of the Sales Management Agreement, 1,600,000 shares of the Company’s common stock under the warrants expired.  The fair value of the warrants on the date of issuance as calculated using the Black-Scholes model was $51,390, using the following weighted average assumptions:  exercise price of $0.20 per share; common stock price of $0.08 per share; volatility of 110%; term of three years; dividend yield of 0%; interest rate of 0.41%; and risk of forfeiture of 35%.
On March 2, 2012, the Company issued a warrant to purchase 175,000 shares of the Company’s common stock to a third-party service provider as partial consideration for services rendered to the Company in connection with a financing.  The warrant is exercisable at $0.20 per share and has a term of three years.  The warrant vested upon issuance.  The fair value of the warrant on the date of issuance as calculated using the Black-Scholes model was $5,600, using the following weighted average assumptions:  exercise price of $0.20 per share; common stock price of $0.08 per share; volatility of 131%; term of three years; dividend yield of 0%; interest rate of 0.41%; and risk of forfeiture of 35%.
On June 19, 2012, the Company issued a warrant to purchase 93,750 shares of the Company’s common stock to a third-party service provider as partial consideration for services rendered to the Company in connection with a financing.  The warrant is exercisable at $0.20 per share and has a term of three years.  The warrant vested upon issuance.  The fair value of the warrant on the date of issuance as calculated using the Black-Scholes model was $2,609, using the following weighted average assumptions:  exercise price of $0.20 per share; common stock price of $0.07 per share; volatility of 134%; term of three years; dividend yield of 0%; interest rate of 0.39%; and risk of forfeiture of 35%.
On February 4, 2013, the Company issued a warrant to purchase 250,000 shares of the Company’s common stock in connection with a consulting agreement with an unaffiliated third party for investor relations services.  The warrant is exercisable at $0.035 per share and has a term of three years.  The warrant vested upon issuance.  The fair value of the warrant on the date of issuance as calculated using the Black-Scholes model was $4,072, using the following weighted average assumptions:  exercise price of $0.035 per share; common stock price of $0.035 per share; volatility of 123%; term of three years; dividend yield of 0%; interest rate of 0.38%; and risk of forfeiture of 35%.
On March 4, 2013, the Company issued a warrant to purchase 250,000 shares of the Company’s common stock in connection with a consulting agreement with an unaffiliated third party for investor relations services.  The warrant is exercisable at $0.04 per share and has a term of three years.  The warrant vested upon issuance.  The fair value of the warrant on the date of issuance as calculated using the Black-Scholes model was $4,644, using the following weighted average assumptions:  exercise price of $0.04 per share; common stock price of $0.04 per share; volatility of 123%; term of three years; dividend yield of 0%; interest rate of 0.35%; and risk of forfeiture of 35%.
On April 1, 2013, the Company issued a warrant to purchase 250,000 shares of the Company’s common stock in connection with a consulting agreement with an unaffiliated third party for investor relations services.  The warrant is exercisable at $0.04 per share and has a term of three years.  The warrant vested upon issuance.  The fair value of the warrant on the date of issuance as calculated using the Black-Scholes model was $4,696, using the following weighted average assumptions:  exercise price of $0.04 per share; common stock price of $0.04 per share; volatility of 125%; term of three years; dividend yield of 0%; interest rate of 0.36%; and risk of forfeiture of 35%.
On August 2, 2013, the Company issued a warrant to purchase 401,567 shares of the Company’s common stock in connection with a placement agent and advisory services agreement.  The warrant is exercisable at $0.0345 per share and has a term of five years.  The warrant vested upon issuance.  The fair value of the warrant on the date of issuance as calculated using the Black-Scholes model was $23,188.  This fair value calculation used the following weighted average assumptions:  exercise price of $0.0345 per share; common stock price of $0.095 per share; volatility of 141%; term of five years; dividend yield of 0%; interest rate of 1.36%; and risk of forfeiture of 35%.
A summary of warrant transactions during the years ended December 31, 2013 and 2012 is as follows:
		Warrant				Weighted				Aggregate
		Shares				Average				Intrinsic
						Exercise				Value
						Price Per
						Common Share
Outstanding at December 31, 2011			33,381,748			$	0.19			$	--
Issued during the period			14,831,250			$	0.14
Exercised during the period			--				--
Terminated during the period			(2,360,000	)		$	0.17
Outstanding at December 31, 2012			45,852,998			$	0.17			$	--
Issued during the period			1,151,567			$	0.04
Exercised during the period			--				--
Terminated during the period			(10,160,000	)		$	0.33
Outstanding at December 31, 2013			36,844,565			$	0.12			$	95,584
Exercisable at December 31, 2013			36,844,565			$	0.12			$	95,584
Exercisable at December 31, 2012			45,852,998			$	0.17			$	--
Warrants issued by the Company contain exercise prices as determined by the Company’s board of directors, but such exercise prices were not less than the fair market value of the Company's common stock on the date of issuance.  Warrants issued may vest over a period of up to three years and have a maximum term of ten years from the date of issuance.
Information with respect to outstanding warrants and warrants exercisable at December 31, 2013 is as follows:
				Warrants Outstanding										Warrants Exercisable
Range of				Number of				Weighted				Weighted		Number of		Weighted		Weighted
Exercise				Shares				Average				Average		Shares		Average		Average
Prices				Available				Remaining				Exercise		Available for		Exercise		Remaining
				Under				Contractual				Price Per		Purchase		Price Per		Contractual
				Outstanding				Life (Years)				Common		Under		Common		Life (Years)
				Warrants								Share		Outstanding		Share
														Warrants
$	0.03 - 0.04				1,151,567				3			$	0.04		1,151,567	$	0.04		3
$	0.07 - 0.10				23,056,061				4			$	0.09		23,056,061	$	0.09		4
$	0.2				12,636,937				1.2			$	0.2		12,636,937	$	0.2		1.2
					36,844,565				3			$	0.13		36,844,565	$	0.13		3
A summary of the non-vested shares subject to warrants as of December 31, 2013 and 2012 is as follows:
		Warrant				Weighted
		Shares				Average
						Grant Date
						Fair Value
						Per Share
Non-vested at December 31, 2011			3,894,446			$	0.08
Issued during the period			14,831,250			$	0.07
Vested during the period			(17,125,696	)		$	0.07
Terminated during the period			(1,600,000	)		$	0.08
Non-vested at December 31, 2012			--				--
Issued during the period			1,151,567			$	0.04
Vested during the period			(1,151,567	)		$	0.04
Terminated during the period			--				--
Non-vested at December 31, 2013			--				--
As of December 31, 2013, there was no unrecognized compensation cost related to non-vested stock-based compensation arrangements involving warrants.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related-Party Transactions [Abstract]	'
Related Party Transactions	'
	14.	Related-Party Transactions
	Except as disclosed below, there has not been any transaction or series of related transactions to which the Company was a participant during the years ended December 31, 2013 and 2012 involving an amount in excess of $120,000 and in which a related party to the Company had or will have a direct or indirect material interest.
	E. Wayne Kinsey, III, a director of the Company, participated in several financings conducted by the Company during the years ended December 31, 2013 and 2012.  See Note 9 – Convertible Debentures:  Kinsey Convertible Debenture; Note 12 – Convertible Promissory Notes; and Note 13 – Stockholders’ Equity (Deficiency):  Common Stock.
	Zanett Opportunity Fund, Ltd., the beneficial owner of greater than 5% of the Company’s outstanding common stock, participated in several financings conducted by the Company during the year ended December 31, 2012.  See Note 9 – Convertible Debentures:  Zanett Convertible Debentures; and Note 12 – Convertible Promissory Notes.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	15.	Commitments and Contingencies
	TrueLogix Sales Management Agreement
	On December 6, 2011, the Company and TrueLogix entered into a Sales Management Agreement whereby the Company engaged TrueLogix to perform certain duties associated with the sale of the Company’s solutions.  On September 21, 2012, the Company, TrueLogix and the managers of TrueLogix, Colby J. Sanders, Patrick T. Lewis and Howard B. Gee, entered into a Mutual Termination of Sales Management Services Agreement, whereby the parties agreed to terminate effective August 31, 2012, the Sales Management Agreement.  For the year ended December 31, 2012, the Company recorded $18,000 of sales and marketing expense for services provided under the Sales Management Agreement (see Note 13 – Stockholders’ Equity (Deficiency):  Warrants to Purchase Common Stock).
	Lease Agreement – South Carolina
	The Company entered into a lease agreement for its premises located in Little River, South Carolina on January 1, 2006.  The lease agreement had an original term of three years.  In January 2009, the Company agreed to renew the lease agreement for a term of five years, ending on December 31, 2013, at $71,291 per year.  The renewal term contained the same covenants, conditions, and provisions as provided in the original lease agreement.  The Company is currently leasing the premises on a month-to-month basis.
	Litigation with Former Chief Executive Officer
	On September 23, 2011, a civil complaint was filed against the Company and one of its directors, E. Wayne Kinsey, III, in the Court of Common Pleas, County of Horry, State of South Carolina, by William E. Prince, the Company’s former President and Chief Executive Officer.  In his complaint, Mr. Prince alleged breach of contract and fraudulent inducement by the Company against him with regard to his employment agreement and the termination of his employment.  Mr. Prince claimed that he was owed additional compensation under his terminated employment agreement, and sought the recovery of such compensation as well as attorney’s fees and punitive damages.
	On December 4, 2012, the Company, Mr. Kinsey and Mr. Prince entered into a Settlement and Release Agreement with respect to this action.  As part of the settlement, the Company paid $5,000 to Mr. Prince.  In addition, the Company, Mr. Kinsey and Mr. Prince agreed to unconditional mutual releases regarding, among other things, all of the claims made by Mr. Prince in the civil complaint, as amended.
	Litigation with Crystal Enterprises
	On January 12, 2012, a civil complaint was filed against the Company in the United States District Court for the Western District of Washington by Crystal Enterprises, Inc.  In its complaint, Crystal alleged interference with prospective advantage or business expectancy, tortious interference with contract, breach of fiduciary duty, breach of non-disclosure agreement and breach of contact.  Crystal’s allegations centered on discussions among the Company, Crystal, Pendred, Inc. (an affiliate of Crystal) and Biolize Products, LLC, regarding the establishment of a business relationship involving the distribution of the Company’s anolyte and catholyte solutions.  Crystal sought monetary damages as well as attorney fees.  The Company refuted all claims made by Crystal, including the monetary damages claimed by Crystal.
	On June 26, 2013, the Company entered into a Confidential Settlement Agreement (the “Settlement Agreement”) with Crystal and Pendred, Inc. related to the civil complaint in order to resolve the dispute and to avoid further litigation costs associated with defending the litigation.  Pursuant to the Settlement Agreement, neither party admitted to any wrongdoing, the parties agreed to unconditional mutual releases regarding, among other things, all of the claims made by Crystal in the civil complaint and the Company issued 450,000 shares of its common stock to Crystal (see Note 13).  The total expense associated with the issuance of these shares was $26,550, representing the fair market value of the shares of common stock on the date of issuance to Crystal ($0.059 per share).

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	16.	Subsequent Events
	On February 25, 2014, the Company issued an aggregate of 206,250 shares of its common stock, at a per share price of $0.08, as settlement of $16,500 of director fees due certain members of the Company’s board of directors for services rendered for the period comment September 1, 2013 through December 31, 2013.  The quoted market price of the Company’s common stock on the date the issuance was approved by the Company’s board of directors was $0.08 per share.
	On January 8, 2014, the Company sold 350,000 shares of its common stock to an individual investor for an aggregate purchase price of $25,200, or $0.072 per share.
	On March 14, 2014, the Company issued 250,000 shares of its common stock in connection with a consulting agreement with an unaffiliated third party for marketing services.  The total expense associated with the issuance of these shares was $20,000, representing the fair market value of the shares on the date of issuance ($0.08 per share).

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary.  All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
	Although the Company regularly assesses these estimates, actual results could differ materially from these estimates.  Changes in estimates are recorded in the period in which they become known.  The Company based its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.  Actual results may differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate.  All of these estimates reflect management's best judgment about current economic and market conditions and their effects based on information available as of the date of these consolidated financial statements.  If such conditions persist longer or deteriorate further than expected, it is reasonably possible that the judgments and estimates could change.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.  The Company’s financial instruments that are exposed to concentration of credit risks consist primarily of cash.  The Company maintains its cash in bank accounts which, at times, exceed federally-insured limits.
	The Company sells its products to customers in diversified industries and geographical regions.  During the year ended December 31, 2013, four customers accounted for 22%, 14%, 14% and 11%, respectively, of revenues.  For the year ended December 31, 2012, two customers accounted for 35% and 29%, respectively, of revenues.  No other customer accounted for more than 10% of the Company’s revenues during the year ended December 31, 2013 or 2012.  We regularly evaluate the creditworthiness of the Company’s customers.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable consist of trade receivables recorded at original invoice amount, less any allowance for uncollectible accounts.  Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest.  Trade receivables are periodically evaluated for collectability by considering a number of factors, including the length of time an invoice is past due, the customer’s creditworthiness and historical bad debt experience.  Changes in the estimated collectability of trade receivables are recorded in the results of operations for the period in which the estimate is revised.  Trade receivables that are deemed uncollectible are offset against the allowance for uncollectible accounts.  The Company generally does not require collateral for trade receivables.
Inventory	'
	Inventory
	Inventory is recorded at the lower of cost or market using the first-in, first-out method.  The Company determines its reserve for obsolete inventory by considering a number of factors, including product shelf life, marketability, and obsolescence.  The Company determines the need to write down inventories by analyzing product expiration, market conditions, and salability of its products.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost less allowances for depreciation.  The straight-line method of depreciation is used for all property and equipment.  Repair and maintenance costs are expensed as incurred.  Equipment is depreciated over an estimated useful life ranging from three to seven years.   Leasehold improvements are depreciated over the shorter of the original term of lease or the estimated useful life of the improvement.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments, which include cash, accounts receivable, lease receivables, accounts payable and accrued expenses, approximate their fair values due to their short maturities.
	The fair value of the note receivable, notes payable, convertible debentures and convertible promissory notes approximate fair value since each of these investments are at market rates currently available to the Company.
Long-Lived Assets	'
	Long-Lived Assets
	The Company reviews its long-lived assets, which include property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable in accordance with Accounting Standards Codification (“ASC”) 360-10-35-15, “Property, Plant and Equipment-Impairment or Disposal of Long-Lived Assets.”  Recoverability of these assets is evaluated by comparing the carrying value of the assets to the undiscounted cash flows estimated to be generated by the assets over their remaining economic life.  If the undiscounted cash flows are not sufficient to recover the carrying value of the assets, the assets are considered impaired.  The impairment loss is measured by comparing the fair value of the assets to their carrying value.  Fair value is determined by either a quoted market price, if any, or a value determined by a discounted cash flow technique.  There were no material impairment charges related to the Company’s property and equipment during the years ended December 31, 2013 or 2012.
Revenue Recognition	'
	Revenue Recognition
	General
	Revenue is recognized when persuasive evidence of an arrangement exists, title and risk of ownership have passed, the sales price is fixed or determinable and collectability is probable.  Generally, these criteria are met at the time the product is shipped.  Provisions for estimated returns, rebates and discounts are provided for at the time the related revenue is recognized.  Freight revenue billed to customers is included in sales and the related shipping expense is included in cost of sales.  Service revenue is recognized in the period the service is performed or ratably over the period of the related service contract.
	Leases
	When the Company leases its equipment, the accounting involves specific determinations, which often involve complex provisions and significant judgments.  The four criteria of the accounting standard that the Company uses in the determination of a sales-type lease or operating-type lease are: (a) a review of the lease term to determine if it is equal to or greater than 75% of the economic life of the equipment; (b) a review of the minimum lease payments to determine if they are equal to or greater than 90% of the fair market value of the equipment; (c) a determination of whether or not the lease transfers ownership to the lessee at the end of the lease term; and (d) a determination of whether or not the lease contains a bargain purchase option.  If the lease transaction meets one of the four criteria, then it is recorded as a sales-type lease; otherwise, it is recorded as an operating-type lease.  Additionally, the Company assesses whether collectability of the lease payments is reasonably assured and whether there are any significant uncertainties related to costs that it has yet to incur with respect to the lease.
	When a customer enters into a sales-type lease agreement, the sales and cost of sales are recognized at the inception of the lease.  The sales-type lease consists of the sum of the total minimum lease payments less unearned interest income and estimated executory cost.  Minimum lease payments are part of the lease agreement between the Company (lessor) and the customer (lessee).  The discount rate implicit in the sales-type lease is used to calculate the present value of minimum lease payments, which the Company records as a lease receivable.  The minimum lease payment consists of the gross lease payments net of executory costs and contingencies, if any.  Unearned interest income is amortized over the lease term to produce a constant periodic rate of return on net investment in the lease.  While revenue is recognized at the inception of the lease, the cash flow from the sales-type lease occurs over the course of the lease, which results in interest income.  Sales-type lease revenue consists of the initial sale of the equipment shipped and the interest and license elements of the lease payments as they are earned.
	When a customer enters into an operating-type lease agreement, equipment lease revenue is recognized on a straight-line basis over the life of the lease, while the cost of the leased equipment is depreciated over its estimated useful life.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under ASC 740, “Income Taxes” (“ASC 740”).  ASC 740 requires that the Company recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carry-forwards to the extent they are realizable.  The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.  While the Company has considered future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance, in the event the Company was to determine that it would be able to realize the deferred tax assets in the future in excess of the net recorded amount, an adjustment to the deferred tax asset would increase income in the period such determination was made.  Likewise, deferred tax assets are reduced by a valuation allowance, when in the Company’s opinion, it is more likely than not that some portion or all of the deferred tax asset will not be realized.
Research and Development	'
	Research and Development
	The Company expenses research and development costs as incurred.
Stock-based compensation	'
	Stock-Based Compensation
	The Company accounts for stock-based payments to employees in accordance with ASC 718, “Stock Compensation” (“ASC 718”).  Stock-based payments to employees include issuances of stock, grants of stock options and issuance of warrants that are recognized in the consolidated statement of operations based on their fair values at the date of grant or issuance.
	The Company accounts for stock-based payments to non-employees in accordance with ASC 718 and Topic 505-50, “Equity-Based Payments to Non-Employees.”  Stock-based payments to non-employees include issuances of stock, grants of stock options and issuances of warrants that are recognized in the consolidated statement of operations based on the value of the vested portion of the award over the requisite service period as measured at its then-current fair value as of each financial reporting date.
	The Company calculates the fair value of option grants and warrant issuances utilizing the Black-Scholes pricing model.  The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.  ASC 718 requires forfeitures to be estimated at the time stock options are granted and warrants are issued to employees and non-employees, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant.  The Company estimates forfeiture rates for all unvested awards when calculating the expense for the period.  In estimating the forfeiture rate, the Company monitors both stock option and warrant exercises as well as employee termination patterns.
	The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.
	During the years ended December 31, 2013 and 2012, the Company recorded stock-based compensation expense as follows:
		Year Ended
		December 31,
		2013		2012
	General and administrative	$	90,969	$	79,485
	Sales and marketing		10,220		65,674
	Research and development		4,380		19,380
	Total	$	105,569	$	164,539
	For the years ended December 31, 2013 and 2012, the Company recorded stock-based compensation expense related to stock options granted to employees and directors of $48,607 and $144,084, respectively.  For the years ended December 31, 2013 and 2012, the Company recorded stock-based compensation expense related to common stock and warrants issued to non-employees of $56,962 and $20,455, respectively.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive.  The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.
	For the year ended December 31, 2013, diluted net loss per share did not include the effect of 4,980,254 shares of common stock issuable upon the exercise of outstanding stock options, 36,844,565 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debentures, as their effect would be anti-dilutive.
	For the year ended December 31, 2012, diluted net loss per share did not include the effect of 5,813,587 shares of common stock issuable upon the exercise of outstanding stock options, 45,852,998 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debentures, as their effect would be anti-dilutive.
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made to prior periods to conform to current presentations.
Recent Accounting Pronouncements Applicable to the Company	'
	Recent Accounting Pronouncements Applicable to the Company
	The Company does not believe there are any recently issued, but not yet effective, accounting standards that would have a significant impact on the Company’s financial position or results of operations.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Schedule of recognized stock-based compensation expense	'
		Year Ended
		December 31,
		2013		2012
	General and administrative	$	90,969	$	79,485
	Sales and marketing		10,220		65,674
	Research and development		4,380		19,380
	Total	$	105,569	$	164,539

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property and Equipment [Abstract]	'
Components of property and equipment, on a net basis	'
		Year Ended
		December 31,
		2013			2012
	Leasehold improvements	$	328,977		$	328,977
	Equipment		437,504			203,368
			766,481			532,345
	Less:  Accumulated depreciation		(421,597	)		(249,363	)
		$	344,884		$	282,982

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses [Abstract]	'
Components of accrued expenses	'
		Year Ended
		December 31,
		2013		2012
	Accrued compensation	$	--	$	115,000
	Accrued interest		24,321		21,330
	Accrued auditing fees		22,000		22,000
	Accrued other expenses		1,633		1,633
		$	47,954	$	159,963

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Summary of difference between statutory federal income tax rate and effective income tax rate	'
		Years Ended
		December 31,						December 31,
		2013						2012
		Amount			Percent			Amount			Percent
	Income tax provision at federal statutory rate	$	(622,626	)		34	%	$	(654,669	)		34	%
	Effect of state taxes, net of federal benefit		(54,938	)		3			(57,765	)		3
	Change in valuation allowance		679,700			(37	)		712,367			(37	)
	Other		(2,136	)		--			67			--
		$	--			--	%	$	--			--	%
Summary of tax effects of temporary differences and net operating loss carryforwards rise to deferred taxes	'
		Years Ended
		December 31,
		2013			2012
	Net operating loss	$	6,710,397		$	6,105,330
	Depreciation and amortization		53,604			--
	Stock based compensation		309,208			286,075
	Total gross deferred tax assets		7,073,209			6,391,405
	Valuation allowance		(7,073,209	)		(6,391,405	)
	Net deferred tax assets	$	--		$	--

Stockholders_Equity_Deficiency1

Stockholders' Equity (Deficiency) (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of share based compensation activity roll forward	'
			Stock				Weighted				Aggregate
			Option				Average				Intrinsic
			Shares				Exercise				Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2011			300,000			$	0.08			$	--
	Granted during the period			6,346,920				0.18
	Exercised during the period			--				--
	Terminated during the period			(833,333	)		$	0.1
	Outstanding at December 31, 2012			5,813,587			$	0.18			$	--
	Granted during the period			--				0.18
	Exercised during the period			--				--
	Terminated during the period			(833,333	)		$	0.2
	Outstanding at December 31, 2013			4,980,254			$	0.18			$	55,605
	Exercisable at December 31, 2013			3,313,586			$	0.12			$	42,136
	Exercisable at December 31, 2012			1,806,793			$	0.1			$	--
Schedule of share-based compensation, outstanding options and options exercisable	'
					Stock Options Outstanding										Stock Options Exercisable
	Exercise				Number of				Weighted				Weighted		Number of		Weighted		Weighted
	Price				Shares				Average				Average		Shares		Average		Average
					Available				Exercise				Remaining		Available for		Exercise		Remaining
					Under				Price Per				Contractual		Purchase		Price Per		Contractual
					Outstanding				Common				Life (Years)		Under		Common Share		Life (Years)
					Stock				Share						Outstanding
					Options										Stock
															Options
	$	0.08				300,000			$	0.08				0.3		300,000	$	0.08		0.3
	$	0.1				2,180,253			$	0.1				5.2		2,180,253	$	0.1		5.2
	$	0.2				833,333			$	0.2				8.3		833,333	$	0.2		8.3
	$	0.3				1,666,668			$	0.3				8.3		--		--		--
						4,980,254			$	0.18				6.4		3,313,586	$	0.12		5.5
Schedule of nonvested share activity	'
			Stock				Weighted
			Option Shares				Average
							Grant Date
							Fair Value
							Per Share
	Non-vested at December 31, 2011			--				--
	Granted during the period			6,346,920			$	0.05
	Vested during the period			(1,506,793	)		$	0.05
	Terminated during the period			(833,333	)		$	0.05
	Non-vested at December 31, 2012			4,006,794			$	0.05
	Granted during the period			--				--
	Vested during the period			(1,506,793	)		$	0.05
	Terminated during the period			(833,333	)		$	0.05
	Non-vested at December 31, 2013			1,666,668			$	0.05
Warrant [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of share based compensation activity roll forward	'
			Warrant				Weighted				Aggregate
			Shares				Average				Intrinsic
							Exercise				Value
							Price Per
							Common Share
	Outstanding at December 31, 2011			33,381,748			$	0.19			$	--
	Issued during the period			14,831,250			$	0.14
	Exercised during the period			--				--
	Terminated during the period			(2,360,000	)		$	0.17
	Outstanding at December 31, 2012			45,852,998			$	0.17			$	--
	Issued during the period			1,151,567			$	0.04
	Exercised during the period			--				--
	Terminated during the period			(10,160,000	)		$	0.33
	Outstanding at December 31, 2013			36,844,565			$	0.12			$	95,584
	Exercisable at December 31, 2013			36,844,565			$	0.12			$	95,584
	Exercisable at December 31, 2012			45,852,998			$	0.17			$	--
Schedule of share-based compensation, outstanding options and options exercisable	'
					Warrants Outstanding										Warrants Exercisable
	Range of				Number of				Weighted				Weighted		Number of		Weighted		Weighted
	Exercise				Shares				Average				Average		Shares		Average		Average
	Prices				Available				Remaining				Exercise		Available for		Exercise		Remaining
					Under				Contractual				Price Per		Purchase		Price Per		Contractual
					Outstanding				Life (Years)				Common		Under		Common		Life (Years)
					Warrants								Share		Outstanding		Share
															Warrants
	$	0.03 - 0.04				1,151,567				3			$	0.04		1,151,567	$	0.04		3
	$	0.07 - 0.10				23,056,061				4			$	0.09		23,056,061	$	0.09		4
	$	0.2				12,636,937				1.2			$	0.2		12,636,937	$	0.2		1.2
						36,844,565				3			$	0.13		36,844,565	$	0.13		3
Schedule of nonvested share activity	'
			Warrant				Weighted
			Shares				Average
							Grant Date
							Fair Value
							Per Share
	Non-vested at December 31, 2011			3,894,446			$	0.08
	Issued during the period			14,831,250			$	0.07
	Vested during the period			(17,125,696	)		$	0.07
	Terminated during the period			(1,600,000	)		$	0.08
	Non-vested at December 31, 2012			--				--
	Issued during the period			1,151,567			$	0.04
	Vested during the period			(1,151,567	)		$	0.04
	Terminated during the period			--				--
	Non-vested at December 31, 2013			--				--

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Basis of Presentation (Textual)	'	'
Working capital deficiency	$1,002,871	'
Accumulated deficit	($19,480,652)	($17,649,399)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	$105,569	$164,539
General and administrative [Member]	'	'
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	90,969	79,485
Sales and marketing [Member]	'	'
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	10,220	65,674
Research and development [Member]	'	'
Schedule of recognized stock-based compensation expense	'	'
Stock-based compensation expense	$4,380	$19,380

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	Customer	Customer
Summary of Significant Accounting Policies (Textual)	'	'
Property and equipment, estimated useful life	'Ranging from three to seven years.	'
Recorded stock-based compensation expense related to stock options and warrants	$105,569	$164,539
Material impairment charges related to property and equipment	0	0
Criteria for determination of lease type	'(a) a review of the lease term to determine if it is equal to or greater than 75% of the economic life of the equipment; (b) a review of the minimum lease payments to determine if they are equal to or greater than 90% of the fair market value of the equipment; (c) a determination of whether or not the lease transfers ownership to the lessee at the end of the lease term; and (d) a determination of whether or not the lease contains a bargain purchase option. If the lease transaction meets one of the four criteria, then it is recorded as a sales-type lease; otherwise, it is recorded as an operating-type lease.	'
Number of customers	4	2
Stock Options [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Anti-dilutive securities	'	5,813,587
Warrant [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Anti-dilutive securities	36,844,565	45,852,998
Convertible Debt Securities [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Anti-dilutive securities	4,823,750	4,823,750
Employees [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Recorded stock-based compensation expense related to stock options and warrants	48,607	144,084
Anti-dilutive securities	4,980,254	'
Nonemployees [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Recorded stock-based compensation expense related to stock options and warrants	$56,962	$20,455
Sales revenue, segment [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Customers accounted for total revenue	'No other customer accounted for more than 10%	'No other customer accounted for more than 10%
Sales revenue, segment [Member] | Customer one [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Concentration risk, percentage	22.00%	35.00%
Sales revenue, segment [Member] | Customer two [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Concentration risk, percentage	14.00%	29.00%
Sales revenue, segment [Member] | Customer three [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Concentration risk, percentage	14.00%	'
Sales revenue, segment [Member] | Customer four [Member]	'	'
Summary of Significant Accounting Policies (Textual)	'	'
Concentration risk, percentage	11.00%	'

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory (Textual)	'	'
Parts and materials	$126,952	$82,566
Reclassification of equipment from finished goods inventory to fixed assets	$17,487	$138,336

Note_Receivable_Details

Note Receivable (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note Receivable (Textual)	'	'
Installment of note payment	$1,250	'
Installment periods for notes receivable	'34 months	'
Imputed interest rate on note receivable	3.00%	'
Notes receivable related parties adjusted with accounts payable	4,172	6,414
Note receivable	'	7,762
Interest income related to note receivable	$74	$714

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Components of property and equipment, on a net basis	'	'
Leasehold improvements	$328,977	$328,977
Equipment	437,504	203,368
Property and equipment, Gross	766,481	532,345
Less: Accumulated depreciation	-421,597	-249,363
Property and equipment, net	$344,884	$282,982

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Components of accrued expenses	'	'
Accrued compensation	'	$115,000
Accrued interest	24,321	21,330
Accrued auditing fees	22,000	22,000
Accrued other expenses	1,633	1,633
Accrued liabilities, total	$47,954	$159,963

Customer_Deposits_Details

Customer Deposits (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Customer Deposits (Textual)	'	'
Customer deposits	$38,109	$36,109
Deposit received	$2,000	'

Convertible_Debentures_Details

Convertible Debentures (Details) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Apr. 26, 2007

Dec. 31, 2012

Aug. 17, 2012

Jul. 07, 2011

Aug. 17, 2012

Aug. 21, 2012

Aug. 22, 2013

Aug. 31, 2012

Jul. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Aug. 21, 2012

Aug. 17, 2012

Sep. 23, 2011

Jul. 07, 2011

April 2007 Convertible Debenture [Member]

April 2007 Convertible Debenture [Member]

April 2007 Convertible Debenture [Member]

Kinsey Convertible Debenture [Member]

Kinsey Convertible Debenture [Member]

Kinsey Convertible Debenture [Member]

Kinsey Convertible Debenture [Member]

Kinsey Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Zanett Convertible Debenture [Member]

Through July 6, 2012 [Member]

Through July 6, 2012 [Member]

Convertible Debentures (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible debenture issued, Principal amount

'

'

'

'

$25,000

'

'

$150,000

'

'

'

'

'

'

'

$491,690

'

$100,000

$376,125

Convertible debenture, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

31-Aug-15

'

'

'

'

'

'

'

Convertible debenture, Interest Rate

'

'

'

'

12.00%

'

'

8.00%

'

'

'

'

'

'

'

8.00%

'

8.00%

8.00%

Convertible debenture,Interest expense

45,913

69,643

2,992

3,008

'

7,414

'

'

'

'

'

'

'

38,090

32,802

'

'

'

'

Common stock issued pursuant to the Secured Notes

'

'

'

'

'

'

'

'

193,895

'

400,947

4,761,250

476,125

'

'

'

'

'

'

Outstanding principal

476,125

476,125

25,000

25,000

'

'

1,500,000

'

'

'

'

'

'

'

476,125

'

'

'

'

Accrued and unpaid interest on convertible debt

'

'

$10,441

$7,450

'

'

'

'

$13,348

'

$38,090

'

'

'

$13,880

$33,800

'

'

'

Promissory Note Convertible debenture, Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

Convertible debenture, Conversion Price

'

'

'

'

$0.40

'

$0.10

$0.10

'

'

'

'

'

'

'

$0.10

'

'

$0.10

Condition for conversion of debt amount to common stock

'

'

'

'

'

'

'

'

'

'

'

'The occurrence of the merger or acquisition of the Company or if the average closing price of the Company's common stock for any period of ten consecutive trading days is greater than or equal to $0.15 per share.

'

'

'

'

'

'

'

Common stock quoted market price

'

'

'

'

'

'

'

'

$0.07

$0.07

$0.10

$0.05

'

'

'

'

$0.06

'

$0.07

Note_Payable_Details

Note Payable (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
			Asset Purchase Agreement [Member]
			Machine
Note Payable (Textual)	'	'	'
Number of machines purchase agreement	'	'	19
Purchase price of asset	'	'	$190,000
Payment in closing of asset purchase agreement	'	'	38,000
Issuance of promissory note principal balance	'	'	152,000
Convertible promissory notes, interest percentage	'	'	7.00%
Convertible promissory notes, maturity date	'	'	1-Aug-13
Periodic payment	'	'	6,805
Description of payment term	'	'	'Twenty-four monthly payments.
Interest expense	'	'	4,086
Notes Payable	'	'	122,059
Notes payable current portion	75,513	'	75,513
Note payable long term portion	$46,546	'	$46,546

Convertible_Promissory_Notes_D

Convertible Promissory Notes (Details) (USD $)

Sep. 13, 2013

Feb. 04, 2013

Dec. 07, 2012

Aug. 17, 2012

Jun. 19, 2012

Mar. 02, 2012

Feb. 28, 2012

Feb. 02, 2012

Jan. 24, 2012

Aug. 17, 2012

Aug. 21, 2012

Sep. 23, 2011

Aug. 21, 2012

Sep. 23, 2011

Kinsey convertible promissory notes [Member]

Kinsey convertible promissory notes [Member]

Kinsey convertible promissory notes [Member]

Zanett convertible promissory notes [Member]

Zanett convertible promissory notes [Member]

Convertible Promissory Notes (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible promissory notes, face amount

'

'

'

'

'

'

'

'

'

'

'

$400,000

'

$100,000

Convertible promissory notes, interest percentage

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

8.00%

Convertible promissory notes, conversion price

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

Accrued and unpaid interest

'

'

'

'

'

'

'

'

'

$28,844

'

'

$7,321

'

Common stock issued pursuant to the Secured Notes

'

'

'

'

'

'

'

'

'

4,000,000

'

'

122,017

'

Quoted market price of common stock

$0.08

$0.04

$0.05

$0.50

$0.07

$0.08

$0.08

$0.08

$0.08

$0.06

$0.06

'

'

'

Stock Issued Period Shares

'

'

'

'

'

'

'

'

'

480,733

'

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary of difference between statutory federal income tax rate and effective income tax rate	'	'
Income tax provision at federal statutory rate, Amount	($622,626)	($654,669)
Income tax provision at federal statutory rate, Percent	34.00%	34.00%
Effect of state taxes, net of federal benefit, Amount	-54,938	-57,765
Effect of state taxes, net of federal benefit, Percent	3.00%	3.00%
Change in valuation allowance, Amount	679,700	712,367
Change in valuation allowance, Percent	-37.00%	-37.00%
Other, Amount	-2,136	67
Other, Percent	'	'
Total, Amount	'	'
Total, Percent	'	'

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of tax effects of temporary differences and net operating loss carryforwards rise to deferred taxes	'	'
Net operating loss	$6,710,397	$6,105,330
Depreciation and amortization	53,604	'
Stock based compensation	309,208	286,075
Total gross deferred tax assets	7,073,209	6,391,405
Valuation allowance	-7,073,209	-6,391,405
Net deferred tax assets	'	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Taxes (Textual)	'
Valuation allowance attributable to continuing operating losses	$679,700
Federal and state operating losses	$17,990,000
Expiration duration of federal and state operating losses	'Begin to expire in the years 2021 through 2033.

Stockholders_Equity_Deficiency2

Stockholders' Equity (Deficiency) (Details) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Jun. 19, 2012

Mar. 02, 2012

Dec. 06, 2011

31-May-11

Apr. 30, 2011

Jan. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Summary of stock option and warrant transactions

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, Number, Beginning Balance

5,813,587

300,000

'

1,050,000

'

'

'

'

'

13,889,582

45,852,998

33,381,748

'

Granted during the period, Shares

'

6,346,920

'

'

'

'

'

'

'

'

1,151,567

14,831,250

'

Exercised during the period, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

Terminated during the period, Shares

-833,333

-833,333

'

'

'

'

'

'

'

'

-10,160,000

-2,360,000

'

Outstanding shares, Ending balance

4,980,254

5,813,587

'

1,050,000

'

'

'

'

'

'

36,844,565

45,852,998

'

Exercisable, Ending balance

3,313,586

1,806,793

300,000

'

'

'

'

'

'

'

36,844,565

45,852,998

29,487,302

Outstanding, Weighted Average Exercise Price, Beginning Balance

$0.18

$0.08

'

$0.12

'

'

'

'

'

$0.21

$0.17

$0.19

'

Grants in Period, Weighted Average Exercise Price

$0.18

$0.18

'

'

$0.07

$0.08

$0.08

$0.09

$0.07

$0.13

$0.04

$0.14

'

Exercises in Period, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

Terminated, Weighted Average Exercise Price

$0.20

$0.10

'

'

'

'

'

'

'

'

$0.33

$0.17

'

Outstanding, Weighted Average Exercise Price, Ending balance

$0.18

$0.18

'

$0.12

'

'

'

'

'

'

$0.12

$0.17

'

Exercisable, Weighted Average Exercise Price

$0.12

$0.10

$0.08

'

$0.20

$0.20

'

'

'

'

$0.12

$0.17

$0.19

Outstanding, Intrinsic Value

'

'

'

$34,475

'

'

'

'

'

$1,848,875

'

'

'

Granted Aggregate Intrinsic Value

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised Aggregate Intrinsic Value

'

'

'

'

'

'

'

'

'

'

'

'

'

Terminated Aggregate Intrinsic Value

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding, Aggregate Intrinsic Value, Ending balance

55,605

'

'

34,475

'

'

'

'

'

'

95,584

'

'

Exercisable, Intrinsic Value

42,136

'

'

'

'

'

'

'

'

'

95,584

'

'

Exercisable, Aggregate Intrinsic Value, Beginning balance

'

'

'

'

'

'

'

'

'

'

'

$46,061

'

Stockholders_Equity_Deficiency3

Stockholders' Equity (Deficiency) (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jun. 19, 2012	Mar. 02, 2012	Dec. 31, 2011	Dec. 31, 2010
Employee Stock Option [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	4,980,254	5,813,587	'	'	300,000	1,050,000
Weighted Average Exercise Price Per Common Share	$0.18	$0.18	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'6 years 4 months 24 days	'7 years 8 months 12 days	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	3,313,586	1,806,793	'	'	300,000	'
Weighted Average Exercise Price Per Common Share	$0.12	$0.10	'	'	$0.08	'
Weighted Average Remaining Contractual Life (Years)	'5 years 6 months	'6 years 1 month 30 days	'	'	'	'
Employee Stock Option [Member] | Range 1 [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Range of exercise prices	$0.08	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	300,000	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.08	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'3 months 18 days	'	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	300,000	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.08	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'3 months 18 days	'	'	'	'	'
Employee Stock Option [Member] | Range 2 [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Range of exercise prices	$0.10	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	2,180,253	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.10	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'5 years 2 months 12 days	'	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	2,180,253	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.10	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'5 years 2 months 12 days	'	'	'	'	'
Employee Stock Option [Member] | Range 3 [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Range of exercise prices	$0.20	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	833,333	1,666,666	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.20	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'8 years 3 months 18 days	'	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	833,333	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.20	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'8 years 3 months 18 days	'	'	'	'	'
Employee Stock Option [Member] | Range 4 [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Range of exercise prices	$0.30	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	1,666,668	1,666,668	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.30	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'8 years 3 months 18 days	'	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	'	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	'	'	'	'	'	'
Warrant [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	36,844,565	45,852,998	'	'	33,381,748	13,889,582
Weighted Average Exercise Price Per Common Share	$0.13	$0.17	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'3 years	'3 years 3 months 9 days	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	36,844,565	45,852,998	'	'	29,487,302	'
Weighted Average Exercise Price Per Common Share	$0.12	$0.17	$0.20	$0.20	$0.19	'
Weighted Average Remaining Contractual Life (Years)	'3 years	'3 months	'	'	'	'
Warrant [Member] | Range 1 [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Range of exercise prices, Lower limit	$0.03	'	'	'	'	'
Range of exercise prices, Upper limit	$0.04	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	1,151,567	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.04	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'3 years	'	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	1,151,567	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.04	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'3 years	'	'	'	'	'
Warrant [Member] | Range 2 [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Range of exercise prices, Lower limit	$0.07	'	'	'	'	'
Range of exercise prices, Upper limit	$0.10	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	23,056,061	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.09	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'4 years	'	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	23,056,061	'	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.09	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'4 years	'	'	'	'	'
Warrant [Member] | Range 3 [Member]	'	'	'	'	'	'
Summary of stock option and warrant transactions	'	'	'	'	'	'
Range of exercise prices	$0.20	'	'	'	'	'
Number of Shares Available under outstanding Option/warrant	12,636,937	2,622,500	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.20	'	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'1 year 2 months 12 days	'	'	'	'	'
Number of Shares Available for Purchase Under Outstanding	12,636,937	2,622,500	'	'	'	'
Weighted Average Exercise Price Per Common Share	$0.20	$0.50	'	'	'	'
Weighted Average Remaining Contractual Life (Years)	'1 year 2 months 12 days	'	'	'	'	'

Stockholders_Equity_Deficiency4

Stockholders' Equity (Deficiency) (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Employee Stock Option [Member]	'	'	'
Summary of the non-vested shares subject to options granted/Warrant	'	'	'
Nonvested, Number, Beginning Balance	4,006,794	'	'
Granted during the period	'	6,346,920	'
Vested during the period	-1,506,793	-1,506,793	'
Terminated during the period	-833,333	-833,333	'
Non-vested Balance	1,666,668	4,006,794	'
Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance	$0.05	'	'
Weighted Average Grant Date Fair Value Per Share, Granted	'	$0.05	'
Weighted Average Grant Date Fair Value Per Share, Vested	$0.05	$0.05	'
Weighted Average Grant Date Fair Value Per Share, Terminated	$0.05	$0.05	'
Weighted Average Grant Date Fair Value Per Share, Ending Balance	$0.05	$0.05	'
Warrant [Member]	'	'	'
Summary of the non-vested shares subject to options granted/Warrant	'	'	'
Nonvested, Number, Beginning Balance	'	3,894,446	'
Granted during the period	1,151,567	14,831,250	'
Vested during the period	-1,151,567	-17,125,696	'
Terminated during the period	'	-1,600,000	'
Non-vested Balance	'	'	'
Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance	'	$0.08	'
Weighted Average Grant Date Fair Value Per Share, Granted	$0.04	$0.07	'
Weighted Average Grant Date Fair Value Per Share, Vested	$0.04	$0.07	'
Weighted Average Grant Date Fair Value Per Share, Terminated	'	$0.08	'
Weighted Average Grant Date Fair Value Per Share, Ending Balance	'	'	'

Stockholders_Equity_Deficiency5

Stockholders' Equity (Deficiency) (Details Textual) (USD $)

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

Nov. 07, 2013

Nov. 05, 2013

Sep. 13, 2013

Aug. 30, 2013

Aug. 23, 2013

Aug. 16, 2013

Aug. 09, 2013

Aug. 05, 2013

Aug. 02, 2013

Jul. 31, 2013

Jun. 26, 2013

31-May-13

Apr. 30, 2013

Feb. 12, 2013

Feb. 04, 2013

Jun. 19, 2012

Feb. 25, 2014

Mar. 14, 2013

Mar. 31, 2013

Feb. 28, 2013

Dec. 07, 2012

Aug. 17, 2012

Mar. 27, 2012

Feb. 28, 2012

Feb. 02, 2012

Jan. 24, 2012

Oct. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Nov. 13, 2013

Jul. 11, 2013

Jun. 28, 2013

Jun. 20, 2013

22-May-13

16-May-13

Mar. 22, 2013

Mar. 01, 2013

Mar. 02, 2012

Oct. 27, 2011

Oct. 05, 2011

Dec. 31, 2012

Dec. 31, 2012

Jan. 31, 2011

Jan. 26, 2011

Jan. 31, 2011

Jan. 26, 2011

Apr. 30, 2011

Apr. 30, 2011

Jun. 19, 2012

Mar. 02, 2012

Dec. 06, 2011

31-May-11

Apr. 30, 2011

Jan. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

23-May-11

Apr. 21, 2011

Jan. 26, 2011

Dec. 31, 2010

Apr. 21, 2011

Apr. 21, 2011

Apr. 21, 2011

23-May-11

23-May-11

Dec. 31, 2012

Jan. 26, 2011

Dec. 31, 2012

Jan. 26, 2011

Dec. 31, 2013

Dec. 31, 2012

Mar. 27, 2012

Dec. 31, 2012

Mar. 27, 2012

Mar. 27, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 27, 2012

Mar. 27, 2012

Dec. 31, 2013

Dec. 31, 2013

Mar. 27, 2012

Mar. 27, 2012

Mar. 27, 2012

Mar. 27, 2012

Mar. 27, 2012

Mar. 27, 2012

David R. LaVance, President and Chief Executive Officer [Member]

Thomas S. Gifford, Executive Vice President, Chief Financial Officer and Secretary

Issuance of warrants [Member]

Issuance of warrants [Member]

Issuance of warrants one [Member]

Issuance of warrants one [Member]

Minimum [Member]

Maximum [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2010 Stock Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

David R. LaVance [Member]

Raymond C. Kubacki [Member]

Valgene L. Dunham [Member]

David R. LaVance, President and Chief Executive Officer [Member]

Thomas S. Gifford, Executive Vice President, Chief Financial Officer and Secretary

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

David R. LaVance, President and Chief Executive Officer [Member]

Thomas S. Gifford, Executive Vice President, Chief Financial Officer and Secretary

Stock Options Issued to Executive Officers March 2012 [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

Stock Options Issued to Non-Executive Directors [Member]

Stock Options Issued to Non-Executive Directors [Member]

Raymond C. Kubacki [Member]

Valgene L. Dunham [Member]

E. Wayne Kinsey, III [Member]

David N Harry [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

Stock Options Issued to Executive Officers March 2012 [Member]

December 31, 2013 [Member]

December 31, 2014 [Member]

December 31, 2013 [Member]

Stock Options Issued to Non-Executive Directors [Member]

Stock Options Issued to Non-Executive Directors [Member]

Stock Options Issued to Non-Executive Directors [Member]

Stock Options Issued to Non-Executive Directors [Member]

Stockholders Deficiency (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Reserved

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

14,000,000

'

'

'

'

'

'

'

'

'

'

'

Common Stock Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

333,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

90,500

'

'

833,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional common shares issued under stock option plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,333,334

'

'

'

'

'

'

'

'

Outstanding shares under stock option plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,844,565

45,852,998

33,381,748

'

'

'

13,889,582

'

'

'

'

'

'

'

'

'

4,980,254

5,813,587

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted during the period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,151,567

14,831,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to non vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of the warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,609

5,600

51,390

'

'

'

'

'

'

349,520

202,078

98,815

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,812

'

'

37,530

'

'

'

'

'

Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

$0.20

$0.20

'

'

'

'

'

'

$0.09

$0.07

'

'

'

'

'

'

'

'

$0.10

'

$0.25

'

'

'

$0.10

'

'

'

'

'

$0.20

'

'

$0.10

'

'

'

'

'

Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134.00%

131.00%

110.00%

130.00%

130.00%

69.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

187.00%

'

'

145.00%

'

'

'

'

'

Common stock purchase after warrant issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

500,000

'

'

93,750

175,000

2,000,000

'

'

'

'

'

'

6,200,000

4,606,061

'

'

1,818,182

1,818,182

969,967

3,100,000

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'3 years

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'5 years

'

'

'

'

'

Expected Dividend Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

10.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

0.00%

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.39%

0.41%

0.41%

1.83%

2.14%

0.27%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.29%

'

'

1.13%

'

'

'

'

'

Risk of Forfeiture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

35.00%

35.00%

35.00%

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

35.00%

'

'

'

'

'

Warrant Maturity Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'3 years

'3 years

'

'10 years

'11 months 1 day

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock not vested expired on termination date, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

833,333

833,333

833,334

673,460

673,460

'

'

'

'

Per share exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

$0.20

$0.30

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.2

0.5

'

'

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-11

'

31-Dec-11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issuance expenses term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Approved grant of options to purchase shares as payment for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

3,000,000

2,000,000

'

'

5,000,000

'

'

'

1,346,920

'

'

'

'

'

Options exercisable price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

$0.20

'

'

'

'

$0.12

$0.17

$0.19

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

'

$541,860

$340,600

$154,820

$309,640

Stock option activity term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'5 years

'

'

'

'

'

Common stock price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

'

$0.25

'

'

'

$0.07

$0.08

$0.08

$0.09

$0.07

$0.13

$0.04

$0.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.05

'

'

$0.05

'

'

'

'

'

Risk of forfeiture

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

'

'

'

Number of shares vest upon achieving target revenue period ending December 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

833,333

'

'

'

'

'

'

'

'

Number of shares vest upon achieving target revenue period ending December 31, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

833,334

'

'

'

'

'

'

'

'

Target revenue for the period ending December 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

Target revenue for the period ending December 31, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

Exercise price of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.04

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

'

'

'

'

'

'

'

'

Exercise price of shares one

'

'

'

'

'

'

'

'

'

'

'

'

$0.05

'

'

'

'

'

$0.04

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.30

'

'

'

'

'

'

'

'

Description for warrant vest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Each warrant vested as follows: 1,550,000 of the shares subject to the warrant became eligible for purchase on May 23, 2011, an additional 86,111 of the shares subject to the warrant became eligible for purchase on and after the first day of each month for a period of seventeen months commencing June 1, 2011, and 86,113 of the shares subject to the warrant became eligible for purchase on November 1, 2012.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued may vest over a period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation cost related to non-vested stock-based compensation arrangements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,451

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost expected to be recognized over weighted average period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'21 months

'

'

'

'

'

Common stock unit sold

15,151,515

1,000,000

228,125

1,000,000

1,700,000

6,803,333

4,833,333

3,333,333

2,803,366

7,366,665

450,000

250,000

'

'

'

1,875,000

'

'

'

'

'

6,250,000

'

375,000

3,125,000

8,750,000

'

'

'

347,222

2,400,000

850,000

800,000

3,333,333

2,666,666

800,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant to purchase common stock shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

937,500

'

'

'

'

'

3,125,000

'

187,500

1,562,500

8,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price of common stock

1,000,000

66,000

'

30,000

97,000

204,100

145,000

115,000

84,101

221,000

'

'

125,000

125,000

'

150,000

'

'

'

'

'

500,000

18,000

30,000

250,000

700,000

'

'

'

25,000

72,000

25,500

24,000

100,000

80,000

24,000

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price of common stock, per share

$0.07

$0.07

$0.08

$0.03

$0.03

$0.03

$0.03

$0.03

$0.03

$0.03

$0.06

$0.05

$0.03

$0.03

$0.04

$0.08

'

'

'

'

'

$0.08

$0.05

$0.08

$0.08

$0.08

'

'

'

$0.07

$0.03

$0.03

$0.03

$0.03

$0.03

$0.03

$0.03

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price of common stock unit sold

'

'

'

'

'

'

'

'

'

'

'

'

90,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Quoted market price of common stock

'

'

$0.08

'

'

'

'

'

'

'

'

'

'

'

$0.04

$0.07

'

'

'

'

$0.05

$0.50

'

$0.08

$0.08

$0.08

'

'

'

'

'

'

'

'

'

'

'

$0.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued under consulting agreement

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

250,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total expense associated with issuance of shares

'

'

'

'

'

'

'

'

'

'

26,550

12,500

11,875

'

'

'

'

'

10,050

'

5,000

'

800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fee related to common stock unit sold

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

52,000

'

'

'

'

'

'

'

36,000

'

'

'

'

2,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for settlement of outstanding amount owed for services, amount

'

'

18,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's common stock issued for services, shares

1,515,152

100,000

'

'

1,533,333

'

'

500,000

'

'

'

'

3,000,000

'

3,333,333

'

206,250

250,000

'

'

100,000

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued to directors

'

'

'

'

'

'

'

'

'

'

'

'

4,166,667

4,166,667

1,485,714

'

'

'

'

'

'

'

360,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair market value of the common stock issued as additional paid-in capital

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Offering Cost

'

$6,600

'

$2,100

$5,460

$9,587

$9,100

$8,050

$5,808

$11,740

'

'

'

'

$7,000

$10,500

'

'

$5,250

$9,125

'

'

'

$2,100

$17,500

$70,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable price of warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

'

'

'

'

'

$0.20

'

$0.20

$0.20

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

$0.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum vesting period of warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'3 years

'

'3 years

'3 years

'3 years

'3 years

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum vesting period of warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Related Party Transactions (Textual)	'	'
Accounts Payable, Related Parties, Noncurrent	$120,000	$120,000
Zanett Opportunity Fund, Ltd [Member]	'	'
Related Party Transactions (Textual)	'	'
Minimum ownership percentage	'	5.00%

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	0 Months Ended				1 Months Ended	12 Months Ended		0 Months Ended	12 Months Ended
	Apr. 30, 2013	Mar. 14, 2013	Feb. 12, 2013	Feb. 04, 2013	Mar. 27, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 04, 2012	Dec. 31, 2012	Dec. 31, 2013
								Mr. Prince [Member]	Sales Management Agreement [Member]	Settlement Agreement [Member]
Commitments and Contingencies (Textual)	'	'	'	'	'	'	'	'	'	'
Annual compensation	'	'	'	'	'	'	'	$5,000	'	'
Sales and marketing expense	'	'	'	'	'	447,832	495,038	'	18,000	'
Lease expiration period	'	'	'	'	'	'3 years	'	'	'	'
Renewed lease expiration period	'	'	'	'	'	'5 years	'	'	'	'
Leases, future minimum payments due, next rolling fiscal 2013	'	'	'	'	'	71,291	'	'	'	'
Common stock issued to Crystal	4,166,667	'	4,166,667	1,485,714	360,000	'	'	'	'	450,000
Common stock issuance expences	'	$20,000	'	'	'	'	'	'	'	$26,550
Common stock, par value	'	'	'	'	'	$0.00	$0.00	'	'	$0.06

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Nov. 07, 2013

Nov. 05, 2013

Aug. 23, 2013

Aug. 05, 2013

Apr. 30, 2013

Feb. 25, 2014

Mar. 14, 2013

Feb. 04, 2013

Dec. 07, 2012

Mar. 27, 2012

Feb. 25, 2014

Jan. 08, 2014

Mar. 14, 2013

Director [Member]

Individual Investor [Member]

Consultant

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event Textual [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's common stock issued for services

'

'

'

'

'

'

'

'

'

'

$16,500

'

'

Company's common stock issued for services, shares

1,515,152

100,000

1,533,333

500,000

3,000,000

206,250

250,000

3,333,333

100,000

10,000

206,250

'

250,000

Common stock share sold

'

'

'

'

'

'

'

'

'

'

'

350,000

'

Aggregate purchase price of common stock sold

'

'

'

'

'

'

'

'

'

'

'

25,200

'

Common stock issuance expences

'

'

'

'

'

'

$20,000

'

'

'

'

'

$20,000

Share issue price

'

'

'

'

'

'

'

'

'

'

$0.08

$0.07

'

Quoted Market Price

'

'

'

'

'

'

'

'

'

'

'

'

$0.08